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Abstract

Inflammatory Regulation of Cysteine Cathepsins
By Blaine Madison Creasy, Ph.D
A Dissertation submitted in partial fulfillment of the requirements for the degree of
Doctorate of Philosophy at Virginia Commonwealth University.
Virginia Commonwealth University, 2008
Major Director: Kathleen L. McCoy
Department of Microbiology and Immunology

Cysteine cathepsins B, L and S are endosomal/lysosomal proteases that participate
in numerous physiological systems. Cathepsin expression and activity are altered during
various inflammatory diseases, including rheumatoid arthritis, atherosclerosis,
neurodegenerative diseases and cancers. Early immune responses to microbial pathogens
are mediated by pattern-recognition receptors, including Toll-like receptors (TLR).
Signaling through TLR causes cell activation and release of inflammatory mediators,
which can contribute to the severity of chronic inflammatory diseases. The impact of TLR
cell activation on cathepsins B, L and S activities was investigated using live-cell
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enzymatic assays. Individual ligands of TLR4, TLR2 and TLR3 increased intracellular
activities of the three cathepsins indicating the involvement of both MyD88-dependent and
-independent pathways. To investigate the role of inflammatory cytokines in regulating
these proteases, a lipopolysaccharide (LPS) non-responsive cell line was utilized. LPS nonresponsive cells co-cultured with LPS responsive macrophages upregulated cathepsin
activities. Furthermore, culture supernatants from LPS-stimulated macrophages increased
cathepsin activities in LPS non-responsive cells, which could be reduced by neutralizing
antibodies to TNF-α or IL-1β. These findings indicate cytokines regulate cathepsin
activities during macrophage responses to TLR stimulation. Using LPS as a model for
inflammation, the ability of the cannabinoids, delta9-tetrahydrocannabinol (THC), and
CP55940 to suppress cysteine cathepsins during an inflammatory response was
investigated. Cannabinoids, including the major psychoactive component of marijuana
THC, modulate a variety of immune responses and have been proposed as possible
therapeutics to control chronic inflammation. Cannabinoids may mediate their effects
through receptor-dependent or independent mechanisms. Cannabinoid receptor subtype 1
(CB1) and receptor subtype 2 (CB2) have differential expression in leukocytes. Dose
response studies showed that 1 nM THC was sufficient to inhibit cathepsin enhancement in
LPS-stimulated cells. P388D1 macrophages expressed CB2 mRNA, but had no detectable
CB1 mRNA indicating a role for the CB2 receptor. Utilizing a CB2-/- macrophage cell
line, the role of CB2 receptor participation in THC inhibition of cysteine cathepsin
upregulation was explored. THC did not affect cathepsin activity in LPS-stimulated cells
lacking CB2 expression. These findings support the possibility of receptor selective
xviii

agonists as therapeutic treatment during inflammatory diseases to prevent cathepsin
involvement in pathological tissue destruction.

xix

Chapter 1: Introduction
The immune system is an intricate organization of multiple cell types required for
effective host response to invading pathogens. The two arms of immunity are innate
immunity, which recognizes invading pathogens in a non-specific manor, and adaptive or
specific immunity. Innate immunity is considered the first line of host defense, and a
number of cells are involved in the initial response to pathogens, including neutrophils,
macrophages, dendritic cells (DC) and natural killer (NK) cells. The adaptive immune
response involves antigen-specific B and T lymphocytes, which lead to antibody formation
and the development of immunological memory. The two types of adaptive immune
responses are cell-mediated immunity and humoral immunity. Cell-mediated immunity
involves T cell-mediated cytotoxicity and further activation of macrophages for enhanced
pathogen killing. Humoral immunity is the antibody-specific arm of immunity and
requires T cell-B cell interaction. The adaptive immune response is dependent on cells
activated during the innate response. The innate response begins within moments of
pathogen invasion and last for a few days, whereas the adaptive response is activated
within 24 hours and continues for weeks.
Immune cells involved in both innate and adaptive immunity express surface
receptors known as pattern recognition receptors (PRR) that recognize invading pathogens
via pathogen-associated molecular patterns (PAMP). Toll-like receptors (TLRs) are one of
2

the most evolutionarily conserved members of PRR. These receptors are especially
important in innate immunity, and genetic mutations in theses receptors leave hosts unable
to eliminate some infections effectively. For instance, people with a mutated TLR-4 gene
are more susceptible to Gram-negative bacterial sepsis (Janeway, 2001). TLR recognition
of commensal microflora in the intestine is required for intestinal homeostasis (Rakoff,
2004). Loss of homeostatic balance in the intestine contributes to diseases, such as chronic
inflammatory bowel disease and Crohn’s disease (Rakoff, 2004). Upon pathogen
recognition through PRR, immune cells are activated to produce chemical mediators, such
as cytokines and chemokines. Subsequent events, such as recruitment of neutrophils and
macrophage activation, lead to direct killing of microbes and inflammation. The five
classic signs of inflammation are heat, swelling with cell infiltration, pain, redness, and
altered function. Inflammation induced by TLRs plays a role in a number of inflammatory
diseases, including rheumatoid arthritis (RA), atherosclerosis and Crohn’s disease (Karin,
2006; Huang, 2007; 2008). Therefore, understanding the effects of TLR activation and
regulation has important implications for not only host responses but also chronic diseases.
Antigen-Presenting Cells and Antigen Processing
Antigen-presenting cells (APC), such as macrophages and DC, are important
players in both arms of immunity. APC play a critical role in initial pathogen recognition
and inflammation leading to acquired immunity. A very important function of
macrophages is phagocytosis. Phagocytosis is defined as the internalization of
extracellular particulate matter by cells; in many cases, this matter is bacterium. The
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internalized pathogen is contained within a vesicle called the phagosome, which then fuses
with more acidic vesicles including endosomes and lysosomes (Janeway, 2001). The
endosomal/lysosomal enzymes are important for pathogen destruction and antigen
presentation. Intracellular proteases within the vesicles help destroy the pathogen and
process proteins that will serve as cell surface antigens to alert other cells of infection.
Cell surface molecules expressed on APC, such as major histocompatibility complex
(MHC) and co-stimulatory molecules, interact with receptors on T cells. T cells, in turn,
proliferate and differentiate into effector cells, and cell-mediated and humoral immunity
are activated.
The MHC class II antigen presentation pathway is initiated in the endoplasmic
reticulum (ER) where MHC class II αβ heterodimers are assembled with the assistance of
invariant chain (Ii), which serves as a molecular chaperone (Honey, 2003). Ii occupies the
peptide-binding groove, thereby preventing premature loading of peptides in the ER and
during trafficking to the endosomal compartments. Once the MHC class II complex
reaches endosomal/lysosomal compartments, Ii is cleaved by lysosomal proteases called
cathepsins, leaving only the class II associated invariant chain peptide (CLIP) bound.
Pathogen destruction and peptide formation occurs simultaneously within the
endosomal/lysosomal compartments. Lysosomal proteases degrade pathogen proteins and
form peptides, which are then loaded into the MHC II peptide-binding groove. The MHC
class II-like molecule HLA-DM in humans or H-2M in mice mediates the exchange of
CLIP for antigenic peptide (Chapman, 2006). The MHC class II-peptide complex is then
transported to the cell surface where interaction with CD4+ T cells occurs.
4

Whereas MHC class II molecule is only expressed on professional APC under
normal conditions, MHC Class I molecule is found on almost all nucleated cells. MHC
class I molecule is constructed of a 45kDa α chain that associates with β2 microglobulin.
MHC class I molecules have binding grooves with closed ends limiting the peptide size to
8-10 amino acids. MHC class I antigen processing pathway does not involve Ii, and
peptides are derived from endogenous cytoplasmic proteins, such as viral proteins.
Antigenic peptides are generated by the proteasome, and unlike the MHC class II pathway
does not involve endosomal/lysosomal proteases. The proteasome is a multi-subunit
molecular complex present in the cytoplasm and nucleus. While the proteasome’s primary
role is to degrade misrouted or improperly assembled proteins, specific subunits are
substituted to form the immunoproteasome. Unlike MHC class II molecules, MHC class I
molecule is not exported from the ER until peptide loading has occurred. Peptides
generated by the proteasome are transported to the ER lumen through the transporter
associated with antigen processing (TAP). Once the peptide is within the ER, it is loaded
into the MHC class I binding groove. This binding, in turn, stabilizes the MHC class I
complex allowing for transport from the ER to the cell surface. Cells expressing MHC
class I-antigen complexes then interact with CD8+ T cells.
The T-cell receptor (TCR) interacts with peptide-loaded MHC molecules on APC.
APC also express co-stimulatory molecules, such as B7-1 (CD80) and B7-2 (CD86),
which interact with co-receptors on T cells. Proper T cell activation requires both TCR
and co-stimulation signals. T cells are divided into two subpopulations based on cell
surface expression of co-receptor CD4 or CD8 proteins. Cytotoxic CD8+ T lymphocytes
5

(CTL) are MHC class I restricted and aid in response to intracellular pathogens by killing
infected cells that are expressing foreign antigen in the context of MHC class I molecules.
CTL contain intracellular proteins, such as perforin and granzymes, which are secreted
from activated CTL. These proteins aid in the destruction of infected cells by punching
holes in their cell membrane, which causes cell death. CD8+ T cells can also induce target
cells to undergo apoptosis via Fas-Fas ligand interaction. This function is particularly
important for killing tumor cells. Tumor cells can evade killing by immune cells by down
regulating Fas expression, shutting off the internal Fas pathway or even expressing Fas
ligand thereby inducing apoptosis of immune cells expressing Fas (Abrams, 2005).
CD4+ T cells exert their effects primarily by cytokine secretion. CD4+ T cells can
further be divided into two subclasses called T helper 1 (Th1) and T helper 2 (Th2) cells.
Another subclass of T cells called T regulator cells also play an important role in immune
regulation. Cytokines produced by Th1 cells act as a positive feedback for APC, increasing
MHC class II expression and inducing cytokine production by APC. Th2 cells are the
humoral immunity helper cell. These cells secrete cytokines, such as interleukin (IL)-4,
and express CD40 ligand that induce antibody class switching and differentiation of B cells
into antibody-producing plasma cells or memory cells. Efficient antigen processing and Bcell activation are required for the memory and longevity of adaptive immunity.
Macrophages
All cells of the immune system arise from pluripotent hematopoietic stem cells in
the bone marrow. These pluripotent cells differentiate into either lymphoid or myeloid
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progenitor cells. Circulating monocytes give rise to macrophages and are derived from
myeloid progenitors (Janeway, 2001). Peripheral blood monocytes circulate throughout
the body before entering tissues and becoming macrophages. Inflammatory stimuli
increase cell recruitment to peripheral sites where macrophage maturation occurs (Gordon,
2005). As described in preceding sections, macrophages play multiple roles in host
defense, including pathogen recognition via PRRs, induction of inflammation,
phagocytosis, antigen presentation and cytotoxic killing. Tissue macrophages also have a
crucial role in tissue homeostasis by clearing senescent cells and debris, and participating
in tissue remodeling (Gordon, 2005). A great amount of heterogeneity exists within
macrophage populations, in part, as a result of specialization due to the local anatomical
microenvironment. Differences among these cell types can often be detected by distinct
expression of cell surface molecules. For instances, Mac-1 molecule is highly expressed
on splenic and peritoneal macrophages, but virtually undetectable on alveolar macrophages
(Gordon, 1992).
Alveolar macrophages are the guardian of the respiratory tract. These phagocytes
are responsible for clearing inhaled debris. These cells are in a quiescent state producing
minimal amounts of inflammatory cytokines and displaying poor phagocytic activity. In
several lung injury models, activated pulmonary macrophages release cytokines tumor
necrosis factor-α (TNF-α) and IL-1β as well as chemokines monocyte chemoattractant
protein-1 and macrophage inflammatory protein-1β, which are associated with the acute
phase response (Fels, 1986). Alveolar macrophages secrete proteases with elastinolytic
activity, which contributes to their role in pulmonary diseases. For example, cigarette
7

smoke induces distinct changes in gene expression leading to an altered activation state of
alveolar macrophages contributing to chronic obstructive pulmonary disease and
emphysema (Heguy 2006; Muley, 1994; Woodruff, 2005).
Microglial cells are within the central nervous system (CNS) making them unique,
since the CNS is considered to be “immune privileged”. Microglia function as
surveillance cells, constantly moving and analyzing the CNS for damaged neurons,
plaques, and infectious agents (Gehrmann, 1995). Similar to macrophages in the rest of
the body, microglia primarily use phagocytic and cytotoxic mechanisms to destroy foreign
materials (Aloisi, 2001). Over-activation or loss of microglial cell regulation contributes
to the severity of several neurological diseases, such as Alzheimer’s disease, Parkinson’s
disease, multiple sclerosis, human immunodeficiency disease, dementia and traumatic
brain injury.
Osteoclasts, found in bones, regulate bone remodeling and are responsible for bone
resorption. They are characterized by high expression of tartrate-resistant acid phosphatase
(TRAP) and cathepsin K as well as other proteases. While not always considered as
macrophages, their high expression of proteases, production and response to proinflammatory cytokines, and contribution to disease make them macrophage-like. Loss of
osteoclast regulation contributes to the bone disease often suffered by aging women,
osteoporosis. Osteoporosis is caused by an imbalance between bone resorption and bone
formation, and over-activation of osteoclasts promotes bone destruction (Holtrop, 1977;
Vaananen, 2000).
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Kupffer cells and splenic macrophages have similar functions. Kupffer cells are
specialized macrophages found within the liver. The primary function of Kupffer cells is
to recycle old red blood cells that no longer are functional. The red blood cell is broken
down by phagocytic action, and the hemoglobin molecule is split. Both globin chains and
the heme iron-containing portion are reutilized (Haubrich, 2004). During liver injury and
inflammation, Kupffer cells secrete cytokines, reactive oxygen species (ROS) and
enzymes, which contribute to hepatocyte destruction. Splenic macrophages within the
white pulp make up approximately 5% of the splenocyte population. Splenic macrophages
are heterogeneous due to the various microenvironments in the spleen and resemble
Kupffer cell function. Via phagocytosis, they remove parasites, bacteria, damaged or old
red blood cells, apoptotic leukocytes, platelets, and other particles circulating in the blood
(Bennett, 1981; Klonizakis, 1981; Nursat, 1988). Functional failure of marginal zone
macrophages impairs the induction of tolerance to cell-associated antigens leading to
autoimmune disease (Miyake, 2007).
Peritoneal macrophages are resident cells in the peritoneal cavity and make up
approximately 85% of the cells present in peritoneal fluid of humans. Due to their
location, they can affect multiple aspects of immunity and have been linked to diseases,
such as endometriosis. Peritoneal macrophages are also potent cytokines producers, which
can be distributed throughout the body, thereby affecting systemic immunity.
Thioglycollate-elicited peritoneal macrophages are commonly used in scientific animal
studies. Thioglycollate recruits bone marrow monocytes that differentiate into
macrophages, which are not quiescent.
9

Monocytes can differentiate in to macrophages or DC depending upon the
environmental signals received. Some stimuli can promote macrophages to differentiate
into DC-like cells as well (Conit, 2008; Saxena, 2003; Shen, 2008). Macrophages can exist
in different activation states depending upon the stimulus. Macrophages respond to a TLR
ligand, such as bacterial lipopolysaccharide (LPS), or interferon-γ (IFN-γ) and become
primed. IFN-γ upregulates MHC class II expression (Boss, 1997) and lysosomal cysteine
cathepsins B and L (Lah, 1995). In this state, they are capable of phagocytosis, antigen
processing and presentation, however their cytotoxic killing is still inefficient (Adams,
1992). Stronger stimuli, such as IL-1β and TNF-α fully activate macrophages to promote
cell killing of tumor cells or pathogens through increased production of nitric oxide and
ROS. These inflammatory mediators can also be produced by primed macrophage and act
in an autocrine manor to activate macrophages fully. Furthermore, macrophages can be
fully activated by a two-step process involving LPS stimulation followed by IFN-γ.
Primed and activated macrophages serve as APC but also have another important immune
function, antibody-dependent cell-mediated cytotoxicity (ADCC). (Janeway, 2001)
Macrophages have high cell surface expression of Fc receptors for IgG, which bind the Fc
portion of IgG. During acquired immune responses, B cells are activated to produce
antigen-specific IgG, which can then bind bacterial cell surface or virally infected cells, a
process termed opsonization. Opsonized infected cells may then be killed by ADCC.
Alternatively, opsonized infected cells or bacteria undergo Fc receptor-mediated
phagocytosis by macrophages. Complement receptors on macrophages can also mediate
phagocytosis of pathogens bound by complement proteins. Macrophages can clear
10

immune complexes formed by immunoglobulin binding to soluble antigen or binding of
complement components to immune complexes. These latter functions are why
macrophages are called scavenger cells.
Macrophages are potent producers of pro-inflammatory cytokines and also promote
other cell types to synthesize cytokines. While under normal conditions the macrophage
serves to protect and maintain tissue homeostasis, during chronic inflammatory diseases
they are a major contributor to pathological tissue destruction. Macrophage activation
through TLRs induces distinct changes in gene expression and promotes upregulation of
proteins involved in tissue destruction. For example, macrophages also secrete a number
of proteases, such as matrix metalloproteases (MMP) and cathepsins. These enzymes
degrade extracellualr matrix components causing tissue damage or facilitating tumor
metastasis.
Cathepsins
Cathepsins are lysosomal proteases that are divided into three groups: cysteine,
serine, and aspartyl based on active site amino acid residues. Lysosomal cysteine
proteases belonging to the papain gene family were first discovered in the 1940s when
cathepsin C was identified. Forty years elapsed before other members were identified and
the amino acid sequences were determined for some mammalian cathepsins (Turk, 2001).
Currently 11 cysteine cathepsins have been identified in humans: cathepsins B, L, H, S, K,
F, V, X, W, O, and C, of which 9 have catalytic activity (Turk, 2001). These enzymes are
synthesized as inactive precursors, which then undergo proteolytic cleavage by another
protease or autocatalytic cleavage to achieve their active form. The pro-enzyme contains
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sugar moieties of mannose-6-phosphate, which targets the enzyme to lysosomal
compartments, where it is transferred through interaction with the mannose-6-phosphate
receptor (Ishidoh, 2002). Once cathepsins reach the proper intracellular compartment,
their activation is regulated by pH, endogenous inhibitors, such as cystatins, and secretion.
Cysteine cathepsins participate in antigen processing that is required for T cell
immune responses (Berdowska, 2004; Hsing, 2005; Reinheckl, 2001; Rudensky, 2006).
Active site-labeling demonstrates active cathepsins B, L, and S in phagosomal
compartments of APC (Lennon-Duménil, 2002). One of the first indicators of the
importance of these proteases in antigen processing was the treatment of macrophages with
ammonium chloride or chloroquine, which increases lysosomal pH, inhibits the MHC class
II antigen processing pathway (Ziegler, 1982). Disruption of lysosomal acidification by
lysosomotropic reagents or treatment of cells with the protease inhibitor leupeptin leads to
accumulation of Ii chain fragments associated with MHC class II molecules (Honey,
2003). Similar to most cysteine cathepsins, aspartyl cathepsins D and E require an acidic
pH for activity; these enzymes belong to the pepsin family. Pepstatin A, an aspartyl
protease inhibitor, interferes with Ii cleavage and processing of intact chicken ovalbumin
antigen, indicating a role for cathepsins D and E in antigen processing as well (Zhang,
2000). While there is some redundancy among theses proteases, studies using genetically
deficient mice indicate specific roles for cathepsins. Not only do cathepsins appear to have
specific roles, but also in many cases various cells types have differential expression or
specific activity. Table 1 gives an overview of selected cathepsin expression, and the
phenotype of genetically deficient mice.
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Table 1
Tissue expression of cathepsins and phenotypes of cathepsin deficient mice.
Protease
Expression
Knockout Phenotype
Reference
Cathepsin B

B cells, DC,

Decreased susceptibility to TNF-α

Honey, 2003

macrophages

induced hepatocyte apoptosis

Guicciardi,
2001

Cathepsin L

Cortical thymic

Decreased CD4+ T cells, decreased NKT Honey, 2003

epithelial cells,

cells, epidermal hyperplasia, hair follicle Hsieh, 2002

macrophages, B cells deficiencies and dilated cardiomyopathy
and DC
Cathepsin S

Cathepsin K

Cathepsin D

B cells, DC,

Decrease MHC II presentation, NKT

Honey, 2003

macrophages, epithelial

cells, deficient germinal center

Shi, 1999,

cells, smooth muscle

formation and impaired class switching

2003

cells

to IgG2a and IgG3

Macrophages and

No immune phenotype but osteopetrotic Saftig, 2000

osteoclasts

phenotype

B cells, DC, and

Dies at day 21 due to atrophy of ileal

Honey, 2003

macrophages

mucosa, lysosomal storage disorder in

Koike, 2000

the CNS neurons
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Cysteine cathepsin regulation is not well elucidated. Cytokines, such as IFN-γ,
TNF-α, IL-1β, IL-6 and IL-10, can regulate cathepsins, however differential regulation
appears to occur among different cell types (Chae, 2007; Fiebiger, 2001, Lah, 1995; Beers,
2003; Watari, 2000), which is discussed later in this chapter. These enzymes can also be
secreted into the extracellular matrix to prevent their over-accumulation within lysosomal
compartments. Endogenous inhibitors, particularly cystatins, regulate cathepsin activity by
binding the active site. Cystatins A, B, C and F are expressed in a number of immune cells
(Kopitar-Jerala, 2006). Cystatins are inversely affected during inflammatory disease,
whereby expression is often decreased, in contrast to cathepsin expression. Cystatins A and
B, also referred to as stefins, are primarily intracellular proteins, whereas cystatin C
contains a peptide signal sequence for extracellular targeting. Cystatin A is expressed in
epidermal cells, neutrophils, hepatocytes, follicular dendritic cells and splenocytes
(Kopitar-Jerala 2006). Gene expression studies show LPS-stimulated monocytes decrease
cystatin A synthesis, possibly allowing increased cathepsin activity during monocyte
differentiation into APC. Opposite effects occur with cystatin B in monocytes
differentiating into macrophages, whereby expression increases (Hashimoto, 1999).
Mutations in this gene are responsible for Unverrich Lundborg disease, a form of epilepsy.
The phenotype of cystatin B deficient mice mimics human disease with progressive ataxia,
myoclonic seizures and apoptotic cerebellar granular cells (Pennachio, 1998).
Furthermore, lack of cathepsin B in cystatin B-/- mice abolish neuronal cell death
implicating cystatin B directly controls cathepsin B involvement in neuronal apoptosis
(Houseweart, 2003). Cystatin C is a very potent inhibitor of cysteine cathepsins with an
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inhibition constant below the nanomolar range (Lindahl, 1992). Decreased cystatin C
expression is associated with a number of diseases, including atherosclerosis and RA.
During DC maturation intracellular cystatin C levels decrease, and incubation of DC with
TNF-α increases cystatin C secretion, thereby increasing intracellular cathepsin activities
(Kopitar-Jerala, 2006). Due to the inverse correlation of cystatins with cathepsins during
disease, both are often investigated.
Recent research on cathepsins focuses on their importance in various types of
pathophysiological processes. Increased cathepsin activity is associated with multiple
tumor types, including breast, lung, brain, thyroid, pancreatic and melanomas. They are
also associated with RA, osteoporosis, arteriolsclerosis, and other chronic inflammatory
diseases (Berdowska, 2004). Cathepsin K, highly expressed in osteoclasts, plays a crucial
role in progression of osteoporosis and has been suggested as a target for therapy.
Hereditary disorders, such as pycnodysostosis and Papillon-Lefevre, and Haim-Munk
syndromes, are linked to mutations in cathepsin genes (Berdowska, 2004). Cathepsins B,
L and S have been extensively studied over the past decade and have a wide range of
physiological roles. These proteases will be discussed in detail. Infiltrating immune cells
are thought to be the major cause of tissue destruction in numerous inflammatory diseases.
Cell types separated by flow cytometry indicate cathepsin expression is highest within the
GR-1+/Mac-1+ myeloid cell population (Joyce, 2004). Therefore, understanding the
regulation of cathepsins and cystatins in macrophage populations has important
implications for controlling tissue damage mediated by theses proteases.
Cathepsin B
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Cathepsin B (Cat B) is ubiquitously expressed in various tissues and is the most
abundant cysteine cathepsin. Protein and mRNA expression is highest in the liver, thyroid
gland, kidney, and spleen (Berdowska, 2004; Honey, 2003). Enhanced expression of Cat
B is prevalent in colon, thyroid, liver, breast, melanoma, and prostate cancers (Berdowska,
2004). Mice deficient in Cat B are not defective at processing ovalbumin and hen egg
lysozyme indicating it is not required for processing these antigens (Duessing, 1998).
However inhibition of Cat B by the selective inhibitor CA074, produces a Th1 immune
response in BALB/c mice infected with Leshmania major allowing them to overcome
disease (Maekawa, 1997). These mice typically promote a Th2 response to L. major and
lack resistance to this infection. The inhibitor alters processing of soluble L. major
antigens suggesting Cat B could be destroying the necessary epitopes required to drive a
Th1 response (Zhang, 2000).
Cat B has a critical role in initiating pancreatitis and TNF-α-induced apoptosis of
hepatocytes based on genetically deficient mice (Guicciardi, 2001). Cat B is released from
lysosomal compartments and interacts with mitochondria triggering release of cytochrome
c. The death ligand TRAIL (tumor necrosis factor-related apoptosis inducing ligand)
triggers apoptosis in a variety of cancer cells. Inhibition of Cat B blocks TRAIL-induced
cell death in oral squamous cell carcinoma implicating its possible role in caspase
activation as well (Nagaraj, 2006). Cat B is capable of degrading extracellular matrix
components such as collagen and elastin, thereby playing a role in angiogenesis (Joyce,
2004). In pancreatic tumors, Cat B expression is highest within angiogenic islets, and Cat
B deficient mice have fewer angiogenic islets overall (Gocheva, 2006). Furthermore,
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Gocheva et. al. examined upregulation of these cathepsins through various stages of tumor
angiogenesis and detected highest enzyme activity at the invasive tumor fronts (Gocheva,
2006). Cat B is detected in fibroblast- and macrophage-like cells at sites of cartilage and
bone destruction, particularly in patients with osteoarthritis and RA (Hashimoto, 2001). In
addition, Cat B activity is increased in centrum semiovale specimens from the brains of
deceased multiple sclerosis patients and is localized to fibrillary tangles and degenerated
neurites of Alzheimer’s disease and dementia patients (Bever, 1994; Bever, 1995;
Berdowska, 2004).
Cat B proteolytic activity plays a role in multiple aspects of immunity, however
little about its regulation is understood. Doxorubicin, a commonly used cancer treatment
drug that induces cell death, increases Cat B expression and activity in tumor cells. This
regulation is mediated by transcription factor NFκB identifying a NFκB binding site in the
Cat B promoter region (Bien, 2003). IFN-γ decreases mRNA expression of Cat B in
microglia, primary alveolar macrophages and macrophage cell lines, however an interferon
response element has not been identified in the Cat B promoter (Liuzzo, 1999). The
murine Cat B gene does contain several SP-1 sites in the promoter region (Qian, 1991). IL6 indirectly increases Cat B activity in osteoblasts through mechanisms involving mitogen
activated protein kinase (MAPK) signaling and cyclic adenosine monophosphate (cAMP)
(Chae, 2007). The effects of inflammatory stimuli, such as LPS or other TLR ligands, on
Cat B have not been well studied. TLR activation can contribute to chronic inflammatory
diseases and may lead to overexpression of this protease. Furthermore, the mechanisms
involved in cathepsin regulation by infectious ligands are unknown. Therefore studies
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investigating the regulation of Cat B by immune modulating substances would be
progression to understanding and controlling activation during disease states.
Cathepsin L
Cathepsin L (Cat L) is also implicated to be important for antigen processing and Ii
degradation in APCs (Honey, 2003; Reinheckl, 2001). Cat L deficient mice have
decreased CD4+ T-cells and NK T-cells due to impaired Ii chain degradation (Honey,
2003). Cortical thymic epithelial cells from Cat L deficient mice cannot properly cleave Ii
to CLIP, causing a decrease in MHC class II surface expression and ultimately affecting
positive selection (Nakagawa, 1998). Cat L also plays an important role in antigen
processing. Unlike Cat B, which possibly destroys the antigenic epitope required for a Th1
response during infection with L. major, Cat L is required for a Th1 response. Inhibition
of Cat L with CLIK148, a Cat L selective inhibitor, exacerbates the disease and increases
Th2 cytokines (Onishi, 2004).
Cat L-/- mice have epidermal hyperplasia and hair follicle deficiencies as well. A
Cat L isoform localizes in the nucleus and processes CDP/Cux transcription factors
involved in cell cycle progression (Goulet, 2004). The CDP/Cux transcription factors are
also involved in hair follicle morphogenesis possibly explaining the hair follicle deficiency
in Cat L-/- mice. This finding has led to the idea that other cathepsins may also be players
in cell cycle regulation. Similar to Cat B, Cat L can hydrolyze extracellular matrix
components, such as collagen and laminin. Low-density lipoprotein receptor deficient mice
on a high fat diet are used as a model for atherosclerosis. Cat L deficiency in this model
reduces the number of atherosclerotic plaques and leukocyte migration due to its role in
18

remodeling of the arterial extracellular matrix (Kitamoto, 2007). Cat L is also increased in
synovial fluid from patients with RA but is not increased in plasma indicating the change
in activity is localized to cells in the synovial joint region (Keyszer, 1998).
Pro-inflammatory cytokines, such as TNF-α and IL-1β, are increased in the
synovial joints of RA patients and are current targets for RA therapy. Both cytokines
stimulate secretion of Cat L from synovial fibroblasts indicating their role in the regulation
of Cat L during inflammatory disease (Huet, 1993). Interestingly a NFκB site has not been
identified in the Cat L promoter region, suggesting these cytokines regulate Cat L through
post-translational mechanisms. Cat L is upregulated in macrophages treated with IFN-γ
correlating with increased antigen processing (Lah, 1995). However, an IFN-γ response
element has not been identified in the Cat L promoter indicating IFN-γ indirectly regulates
Cat L. The promoter region for Cat L contains two AP-2, a SP-1 cluster and a cAMP
response element (CRE) (Ishidoh, 1989). Unique to Cat L is regulation by Ii p41 splice
variant. Studies show p41 binds the Cat L active site inhibiting activity, possibly
protecting important epitopes from degradation (Fineschi, 1997; Bevec, 1997). Other
studies suggest p41 binding stabilizes Cat L allowing it to retain its activity in the
extracellular environment when secreted due to inflammatory stimuli (Fiebiger, 2002).
LPS increases Cat L expression in DC, however these studies did not investigate changes
in enzymatic activity or the effect on macrophages (Lautwein, 2002). It is unclear whether
the effects of LPS are directly due to TLR signaling or to cytokines produced during the
inflammatory response.
Cathepsin S
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Cathepsin S (Cat S) is highly expressed in the spleen, lymph nodes and heart, and
has a role in antigen processing and Ii degradation in APC (Berdowska, 2004; Honey,
2003). Cat S is unique compared to other cathepsins, because it is not tightly regulated by
pH and can retain approximately 70% of its activity at a neutral pH (Turk, 2001). Cat S
deficient mice have decreased MHC class II antigen presentation, deficient germinal center
formation, and impaired immunoglobulin class switching (Honey, 2003). These mice also
have diminished susceptibility to collagen-induced arthritis and autoimmune myasthenia
gravis indicating a possible role in production of autoantigens (Nakagawa, 1999; Yang,
2005).
Similar to Cat B and L, increased Cat S levels are associated with atherosclerosis,
inflammatory myopathies, and prostate, lung, and kidney cancers. Studies indicate Cat S
may be involved in the activation of caspases 3,8, and 9 therefore regulating caspasemediated apoptosis (Zheng, 2005). Endothelial cells from cathepsin S-/- mice poorly
degrade elastin and collagen and display decreased migration across Matrigel or type I
collagen membranes indicating its importance in angiogenesis (Berdowska, 2004). Cat S
produces pro-angiogenic factors derived from laminin IV and degrades anti-angiogenic
factors, thereby increasing angiogenesis (Wang, 2006). Cat S involvement in
atherosclerosis has been reported in numerous studies. Whereas Cat S expression is low in
normal arteries, in patients with atherosclerosis it is highly expressed (Sukhova, 1998).
Deficiency of Cat S in the atherosclerosis mouse model led to decreased plaque size,
number of macrophages, T cells, and increased plaque stability (Sukhova, 2003).
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While Cat S clearly participates in multiple autoimmune and chronic inflammatory
diseases, its regulation is poorly understood. IFN-γ increases Cat S expression in smooth
muscle cells, epithelial cells, and lung tissue (Storm, 2002; Zheng 2005). Studies indicate
IFN regulatory factor-1 (IRF-1) regulates Cat S expression by IFN-γ suggesting an IFN
response (ISRE) element in the Cat S promoter (Storm, 2002). IFN-γ induces expression
of Cat S in alveolar remodeling, and pulmonary emphysema is linked to epithelial cell
apoptosis. However, the role of apoptosis in pulmonary disease is not fully understood
(Zheng, 2005). The 5´ untranslated region of the human Cat S gene contains two SP-1
sites and at least 18 AP1 sites (Shi, 1994). LPS induces Cat S expression in cervical
smooth muscle cells and DC (Lautwein 2002; Watari 2000). LPS leads to the activation of
transcription factors binding AP1, which may contribute to this regulation. LPS also
induces expression of pro-inflammatory cytokines TNF-α, IL-β, and IL-6. Monoclonal
anti-TNF-α antibody partially inhibits LPS upregulation of Cat S mRNA expression in
cervical smooth muscle cells demonstrating cytokine regulation of the enzyme as well. IL6 controls Cat S activity in DC in an indirect way by decreasing cystatin C expression
(Kitamura, 2005). This is particularly important, because over-activation of Cat S
decreases MHC class II expression and suppresses CD4+ T-cell responses.
Regulation of cysteine proteases by TLR ligands other than LPS has not been
studied. Studies using LPS indicate there may be both direct and indirect regulation of
these proteases. Studies investigating TLR regulation and direct signaling effects of
cathepsins would increase our understanding of their regulation during infection and
chronic disease. Furthermore, understanding the role of cytokines in TLR-mediated effects
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on cathepsins could promote finding of new therapeutic treatments.
Toll-Like Receptors
As mentioned previously, initial immune responses to microbial pathogens are
mediated by a family of PRR, called TLRs. TLRs were first identified in Drosophila as an
essential receptor for proper dorso-ventral pattern development in embryos (Lemaitre,
1996). TLR mutations cause flies to be highly susceptible to fungal infections (Hoffmann,
1996). This was an important discovery making researchers aware of the importance of
TLR in immunity and led to the finding of TLR homologues in mammals. Pathogen
recognition via PAMPs play an important role in innate immunity. This initiates acute
inflammatory responses promoting production of cytokines and chemokines. Subsequent
events include recruitment of neutrophils and activation of macrophages leading to the
direct killing of microbes. During this process adaptive immunity may also be activated to
further control infection.
There are 10 TLR identified in humans, named TLR 1-10, and each of these
receptors has different specificity (Pasare, 2004). Table 2 is a summary of TLR ligand
specificity and cellular expression location. TLR-1, 2 and 6 bind lipoproteins from the cell
wall of Gram-positive bacteria, whereas TLR-4 recognizes the Gram-negative bacterial
cell wall component, LPS. TLR-3 plays an important role in viral immunity by recognizing
double stranded RNA. TLR-7 and TLR-8 recognize RNA from single stranded RNA
viruses. Unmethylated CpG DNA found in prokaryotic genomes and DNA viruses is
recognized by TLR-9 (Pasare, 2004). There is also evidence that endogenous ligands such
as oxidized lipids, heat shock proteins and DNA from apoptotic cells can activate these
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TLR

Table 2
TLR pathogen associated molecular patterns.
Pathogen
PAMP

Location

1/2

Gram Positive Bacteria

Triacylated Lipoprotein

Cell Surface

2/6

Gram Positive Bacteria

Peptidoglygan (PGN)

Cell Surface

3

Double Stranded RNA

dsRNA, Poly I:C

Cell Surface and

Viruses

Cytoplasm

4

Gram Negative Bacteria

Lipopolysaccharide (LPS)

Cell Surface

5

Flagellated Bacteria

Bacterial Flaggelin

Cell Surface

7

Single Stranded RNA

ssRNA, Imidazoquinolines

Cytoplasm

ssRNA

Cytoplasm

CpG

Cell Surface and

Viruses
8

Single Stranded RNA
Viruses

9

Bacteria and DNA
Viruses

10

Unknown

Cytoplasm
Unknown

Table derived from: Pasare, 2004.
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Surface

receptors (Karin, 2006; Pasare, 2004) .
TLR signaling pathways have been extensively studied. Cell activation by TLR
requires receptor dimerization. In some cases such as TLR-4, homodimerization occurs;
for others such as TLR-1,2, and 6, heterodimerization plays a role in specificity. TLR-1/2
dimerization leads to specific recognition of triacylated lipoproteins, whereas TLR-2/6
dimers bind diacylated lipoproteins (Takeda, 2004; Trinchieri, 2007). TLR-4 is unique in
that it requires the co-receptor CD14 and a stabilizing protein MD-2 for efficient signaling.
Upon ligand binding these receptors dimerize, and a series of signaling events occurs that
results in cell activation and an inflammatory response. TLR signaling cascades lead to
activation of MAPK pathways and novel transcription factors, including NFκB and AP-1
(Figure 1) (O’Neil, 2006). The cytoplasmic portion of TLR receptors has high similarity
to that of the IL-1 receptor family now referred to as Toll/IL-1receptor domain (TIR)
(Yamamoto, 2004). The importance of the TIR domain was first recognized in the
C3H/HeJ mouse strain, which has a point mutation in the TLR-4 gene that results in the
change of a cytoplasmic proline at position 712 to histidine. Loss of this proline residue
resulted in a dominant negative effect on TLR-4 mediated signaling, and these mice are
hyporesponsive to LPS-induced endotoxic shock (Qureshi, 1999; Poltorak,1998). Among
the first studies of TLR signaling was the identification of the common adaptor protein
MyD88 (myeloid differentiation primary-response gene 88) (Takeuchi, 2000). MyD88 is a
common adaptor protein for all TLRs except for TLR-3, which signals independently of
MyD88 (Figure 1). TLR-4 is unique because it signals through both MyD88-dependent
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Figure 1. Schematic representation of TLR signaling pathways.
Binding of LPS induces TLR-4 receptor dimerization and allows for MyD88 or TIRAP
binding to the TLR cytoplasmic domain. Upon activation of the MyD88-dependent
pathway, IRAK-1, IRAK4 and TRAF6 are recruited to the receptor complex and
activated. TRAF6 then activates TAK-1 and/or ECSIT. Activated TAK-1 phosphorylates
IKKβ, and NFκB translocates into the nucleus. TLR-4 MyD88-independent pathway
involves adaptor molecules TRAM and TRIF, which activate TBK-1. TBK-1 can
crosstalk with MyD88-associated signaling components leading to MAPK and NFκB
activation or activate interferon response factors (IRFs) inducing the production of Type I
IFN. TLR-4 signaling can also activate multiple MAPK pathways independent of MyD88
leading to activation of SRE and AP-1 transcription factors. Binding of dsRNA to TLR-3
activates only the MyD88-independent pathway involving TRIF and leads to the activation
of NFκB and IRFs.
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and independent pathways. MyD88 possesses a TIR domain in the C-terminal portion and
a death domain in the N-terminal portion. TIR-TIR interaction is hypothesized to occur
between TLR receptor and MyD88 when receptor dimerization occurs. MyD88 deficient
mice have diminished responses to all TLR ligands that activate the MyD88 pathway.
MyD88 deficiency yields similar results as individual TLR deficiencies except for in the
case of TLR-3 and TLR-4. Loss of MyD88 delays NFκB activation and TNF-α
production in response to LPS, however responses are not completely abolished. The fact
that MyD88-/- mice still induce responses to TLR-3 and TLR-4 ligands suggesting a
MyD88-independent pathway exists. The TLR-3 ligand dsRNA induces NFκB and IRF3
activation in MyD88-/- cells, and IRF3 interacts with tank binding kinase-1 (TBK-1). This
leads to robust IFN-β production, which is completely independent of MyD88 (O’Neil,
2002; O’Neil 2006; Takeda, 2004).
The TIR-TIR platform leads to recruitment of interleukin-1 receptor associated
kinase-4 (IRAK-4), which interacts with MyD88 through the death domain (Figure 1).
IRAK-4 then phosphorylates IRAK-1. Interestingly, deficiency of IRAK-4 causes severe
impairment in response to TLR-2, -3, -4, and -9 ligands, whereas IRAK-1 deficiency only
partially impairs LPS response (Suzuki, 2002; Swantek, 2000). IRAK-1 then activates
TNF-receptor associated factor-6 (TRAF-6). A series ubiquitinylation reactions occurs on
TRAF-6 and TGF-β activating kinase-1 (TAK-1). TAK-1 then activates the IKK complex
leading to NFκB activation (O’Neil, 2006). The IKK complex is composed of IKKα and
IKKβ, which phosphorylate IκB leading to its degradation. As a result the NFκB subunits
are released and translocate into the nucleus to regulate gene transcription. TRAF-6
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activation can also lead to activation of evolutionary conserved signaling intermediate in
toll pathways (ECSIT) and activation of MAP kinase pathways (O’Neil, 2006). Activation
of MAP kinases leads to activation of NFκB, SRE and AP-1 transcription factors. MAP
kinases are activated by other means as well, although this signaling pathway is not fully
understood (Figure 1). Signaling through TLRs can also lead to activation of
phosphoinositol kinase-3 (PI3K) resulting in Akt activation, which causes phosphorylation
of IκB and activation of NFκB (Jones, 2001). These activated transcription factors induce
transcription of immune modulating proteins, in particular TNF-α, IL-1β, IL-6, IFN-γ,
Type I IFN, IL-12 and IL-10.
Other adaptor proteins have been identified including MyD88 adaptor-like (Mal),
also known as TIRAP, TIR-related adaptor protein inducing interferon (Trif) and Trifrelated adaptor molecule (Tram). Mal plays a role in TLR-4 and TLR-2 signal
transduction, and mice deficient for Mal have a similar phenotype to MyD88-deficient
mice. Rapid induction of TNF-a production is abolished and activation of MAP kinases
and NFκB are delayed (O’Neil, 2002). Trif is recruited to TLR-3 and TLR-4 and is
responsible for interferon response factor-3/7 (IRF3/7) activation via IKK-like kinase,
TBK-1. Trif is thought to be responsible for the IFN-β production in response to TLR-3
and TLR-4 ligands that is absent with other TLRs stimulation.
Differential effects of TLR responses have been extensively studied in
macrophages. For instance, in RAW 264.7 murine macrophage cell line LPS induces
strong IL-1β production that is not seen in response to TLR-2 ligands (Jones, 2001).
Similar to that result is induction of inducible nitric oxide synthase (iNOS) gene
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expression. However, TNF-α production occurs in response to both TLR-2 and TLR-4
ligands (Vogel, 2001). Similar findings are also seen with thioglycollate-elicited
peritoneal macrophages (Jones, 2005). These differences may be attributed to differential
activation of MAPK pathways (Jones, 2001). Studies performed using MyD88-/- mice
reveal the induction of TNF-α, IL-1β, and IL-12 secretion is MyD88-dependent. The time
course of cytokine production shows that TNF-α, IL-6 and IL-12 production peaks at four
to six hours. In the case of TLR-4 signal transduction, cytokine production still occurs but
is delayed without the presence of MyD88. Other genes, such as chemokine CXCL 10 (IP10), IRF-1, and macrophage colony stimulating factor 1 (M-CSF), are regulated
independent of MyD88 (Bjorkbacka, 2004). TLR-3 ligands induce robust IFN-b secretion,
and the rapid TNF-α production seen with other TLRs does not occur (Takeda, 2004;
Trincheiri, 2007).
TLRs are implicated as contributors to severity of numerous diseases that also
involve increased cathepsin activity and expression. Recent human genetic studies indicate
TLR polymorphisms are associated with susceptibility to several diseases (Misch, 2008).
Activation of TLR on tumor cells enhances proliferation and metastasis by increasing
expression of MMPs and integrins (Huang, 2007). Possibly, cathepsins are affected as
well, and infiltrating immune cells appear to have the highest cathepsin expression. In
atherosclerosis, TLR-2 activation of multiple cell types with either endogenous or
exogenous ligands promotes atherogenesis (Tobias, 2007). TLR-2 and TLR-4 expression
is increased on macrophages isolated from the joints of RA patients. Furthermore,
inflammatory cytokine production in response to peptidoglygan (PGN) and LPS is
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increased in cells from diseased patients (Huang, 2007). TLR regulation of cathepsins is
not well elucidated. Hence, my research project investigated the impact of macrophage
stimulation via different TLRs on cysteine cathepsin activities and expression.
Cannabinoids
The plant Cannabis sativa, better known as marijuana, has been used in
traditional medicine for millennia to treat various ailments, including chronic inflammatory
and autoimmune diseases. Delta9-tetrahydrocannbinol (THC), the major psychoactive
component of marijuana, has immune modulating abilities in both humans and
experimental animal models. THC has been used to treat ailments, including but not
limited to pain, asthma, glaucoma, multiple sclerosis, AIDS and cancer (Benamar, 2006;
Klein, 2005). THC along with the endogenous cannabinoids 2-arachidonoylethanolamide
and 2-arachidonoylglycerol (2-AG), as well as synthetic derivatives of THC are currently
being investigated as possible therapeutic candidates.
Cannabinoids, including THC, alter cellular responses by immune cells, in
particular macrophages. THC and its associated derivatives suppress mitogen-induced B
and T lymphocyte proliferation. In addition, THC also suppresses cell-mediated immunity
by decreasing cytotoxic T cell activity. Studies using sheep red blood cell plaque-forming
cell assays suggest THC decreases B cell antibody responses indicating cannabinoids can
affect both arms of adaptive immunity. In other model systems, cannabinoids interfere
with Th1, but not Th2, cytokine production (Cabral, 2005; Klein, 2003). These latter
findings have lead to the hypothesis that cannabinoids skew helper T cell responses toward
humoral immunity while impairing cell-mediated immunity and inflammation. However,
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this hypothesis cannot easily explain diminished IgE response caused by cannabinoid
exposure in an ovalbumin-asthma mouse model (Schatz, 1997). Furthermore,
cannabinoids affect multiple aspects of innate immunity. Cannabinoids impair multiple
macrophage functions, including phagocytosis, antigen processing, and co-stimulatory
activity; all of which are required for CD4+ helper T cell responses (Klein, 2006; LopezCepero, 1986; McCoy, 1995; McCoy, 1999; Spector, 1991). For example, alveolar
macrophages isolated from chronic marijuana users are compromised in their ability to
produce pro-inflammatory cytokines, such as TNF-α and IL-6, in response to LPS
stimulation (Baldwin, 1997). Cannabinoids decrease IFN-γ, IL-1β and TNF-α production
by synovial monocytes in murine models of collagen-induced arthritis (Klein, 2005). Proinflammatory cytokines are key players in the pathogenesis of various diseases including
RA. In addition, macrophage cell line RAW 264.7 treated with THC has attenuated LPSstimulated iNOS gene expression, which is mediated by inhibited NF-κB activation (Jeon,
1996). ROS and nitric oxide are key players in macrophage-mediated pathogen killing.
THC exposure of PEC also decreases APC co-stimulatory activity, ultimately
leading to a defective T-cell response and decreased IL-2 production (Chuchawankul,
2004). THC interferes with the processing of intact protein antigens by macrophages and
increases aspartyl cathepsin D activity (Matvayeva, 2000; McCoy, 1995; McCoy, 1999).
These findings indicate a possible affect of cannabinoids on the enzymes involved in
antigen processing, which may extend to cysteine cathepsins. Cannabinoids, including
THC, may mediate immune modulation through cannabinoid receptors called CB1 and
CB2 (Schatz, 1997). Peripheral leukocytes have been shown to express the CB2 receptor
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or both receptors. In contrast, microglial cells express either the CB1 receptor, or both
receptors (Klein, 2003). Studies utilizing receptor selective agonists, antagonists and
receptor deficient mice indicate the immune modulating effects of cannabinoids are
primarily mediated through the CB2 receptor (Buckley, 2008; Chuchawankul, 2004;
McCoy,1999). However, other reports support the involvement of the CB1 receptor in
immune suppression, particularly in models of endotoxic shock (Cabral, 2005). Recently,
a homozygous CB2 receptor gene polymorphism was found to be associated with RA,
multiple sclerosis and myasthenia gravis, suggesting this may be a genetic risk factor for
autoimmune disease development (Sipe, 2005). The best evidence that cannabinoid
receptors are important for immune regulation is derived from mice lacking both CB1 and
CB2 receptors. These mice are extremely sensitive to developing delayed-type
hypersensitivity and chronic inflammation (Karsak, 2007).
Cannabinoid receptors are seven-transmembrane-spanning G protein-coupled
receptors. CB1 receptor, originally identified in rat cerebral cortex, is primarily expressed
in the CNS (Matsuda, 1990; Thomas, 1992). CB2 receptor was originally identified in the
promyelocytic leukemic cell line HL60 and is prevalent in lymphoid organs (Munro, 1993;
Bouaboula, 1993). Cannabinoid receptors were identified as Gi/o protein-coupled receptors
linked to inhibition of adenylate cyclase, when studies demonstrated submicromolar THC
concentrations decrease cAMP (Howlett, 1984). This finding was confirmed by studies
utilizing pertussis toxin, which inhibits Gi/o protein signaling (Howlett, 1986). The highaffinity radiolabeled ligand [3H]CP55940 led to identification of a binding site in brain
membranes confirming receptor expression (Howlett, 2005). However, 3 µM to10 µM
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THC can have non-receptor-mediated effects by increasing membrane fluidity, thereby
influencing receptor dimerization and synapse formation (Hilliard, 1985). Nonpsychoactive cannabidiol has a very low affinity for CB1 and CB2 receptors, yet has antiinflammatory activity in vitro and in vivo, suggesting a non-receptor-mediated mechanism
(Pertwee, 2005). Additional complexity to this situation may be the involvement of other
receptors besides CB1 and CB2. Endogenous cannabinoids can activate the vanilloid
TRPV1 receptor, and several studies also suggest there may be other cannabinoid receptors
that remain unidentified. In mouse models of inflammatory or neuropathic pain
palmitoylethanolamide produces antinociception by acting on a CB2-like receptor.
Palmitoylethanolamide lacks affinity of the CB2 receptor however the CB2 selective
antagonist SR144528 opposed the antinocieptive effects (Pertwee, 2005). Other studies
using anadamide, WIN55,212-2 and cannabidiol have demonstrated their actions can be
mediated through unidentified non-CB1/non-CB2 receptors particularly in endothelial cells
and the CNS (Begg, 2004). While multiple studies indicate the existence of non-CB1/nonCB2 receptors their specific identities and functions remain unclear.
Since the identification of cannabinoid receptors, studies have been underway to
gain insight into the cellular signaling mechanisms of cannabinoids. While CB1 and CB2
receptors share some similar signaling cascades, distinct differences in the activity of
theses receptors have been identified. G proteins are heterotrimers, and upon activation the
α subunit dissociates from the βγ dimer. The Gi/o a subunit inhibits adenylate cyclase.
Cannabinoid receptor-mediated decreases in cAMP cause decreased protein kinase A
(PKA) activity, which can have multiple biological effects. In contrast, increased PKA
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activity has also been reported via CB1 receptor and may contribute to activation of Raf
and MAPK pathways (Figure 2) (Howlett, 2005). CB1 receptor-mediated increases in
cAMP and PKA activity are due to CB1 association with Gs proteins. Furthermore, CB1
receptor may associate with Gq proteins leading to phospholipase D activation (Howlett,
2005). CB1 receptor signaling can cause increased intracellular Ca++, which may be a
result from the activation of phospholipase C (PLC) (Howlett, 2005). PLC cleaves
membrane-bound PIP2 to IP3, and IP3, in turn, opens ER Ca++ channels, thereby increasing
intracellular Ca++. CB1 signaling affects other ion channels in neural cells as well. CB1
receptor activation of protein kinase C (PKC) and regulation of MAPK have also been
reported (Rubovitch, 2004). Activation of extracellular signal-regulated kinase1 and 2
(ERK1 and ERK2) and jun N-terminal kinases 1 and 2 (JNK1 and JNK2) via p42/44 and
p38 MAPK pathways has been reported as well (Figure 2). One proposed mechanism is
that the G protein βγ dimer provides a scaffold for proteins involved in the MAPK pathway
like PI3K. PI3K activation leads to Akt activation, Akt activates downstream molecules
leading to MAPK activation. This hypothesis was supported when it was demonstrated that
PI3K inhibitors could attenuate cannabinoid activation of MAPK (Bouaboula, 1995).
CB2 receptor signaling is less understood. Whereas CB1 receptor may couple to
Gs proteins leading to increased cAMP and PKA activity, CB2 receptor does not (Demuth
2006). Likewise, CB2 receptor has not been found to associate with Gq proteins.
Stimulation of HL60 cells with cannabinoid agonists does not lead to Akt activation
(Howlett, 2005). However, stimulation of rat microglial cells with 2-AG leads to MAPK
activation, and PKC-dependent activation of MAPK has been reported (Carrier,
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Figure 2. Generalized cannabinoid receptor signaling cascades.
Upon agonists binding to the receptor the G protein subunits disassociate. The α subunit
interacts with adenyl cyclase inhibiting its activity leading to a decrease in cAMP levels
and PKA activity. The βγ subunit can activate PI3K and MKKs. This, in turn leads to the
activation of Akt, p38 MAPK, p42/p44 MAPK and ultimately the activation of JNK1/2
and ERK1/2. PI3K can also activate phospholipase in the plasma membrane, which leads
to the formation of IP3 thereby increasing intracellular Ca++ levels.
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2004; Bouaboula, 1996). THC activates the PI3K/Akt pathway in epithelial cells, which
leads to Raf-1 mediated activation of p42/p44 MAPK (Demuth, 2006). However, opposite
effects with high WIN 55,212-2 concentrations have been reported, whereby inhibition of
p42/p44 MAPK activation occurs in murine splenocytes (Faubert, 2003). The
discrepancies in the literature may due to differences in cannabinoid concentrations or cell
types with differential cannabinoid receptor expression. MAPK regulation by cannabinoid
receptors is not well elucidated but is thought to be involved in the immune modulating
effects seen with cannabinoids.
Multiple synthetic derivatives have been developed as possible therapeutics. THC
is a partial receptor agonist, whereas CP55940 is a full agonist and exerts potent biological
effects. There are also receptor selective agonists, such as JWH-015, which is selective for
CB2 (Klein, 2005). CB2 receptor selective agonists are appealing for therapeutic use,
because they avoid the psychoactive effects accompanied by CB1 activation. Respective
CB1 and CB2 selective antagonists SR141716A and SR144528, inhibit agonist biological
effects. Currently SR141716A, also known as Rimonabant, is used in Canada to treat
obesity and is in clinical trial in the U.S. Other THC-derived drugs such as nabilone
(Cesamet) and dronabinol (Marinol) are currently used in Canada and the U.S. as
antiemetic to treat nausea and vomiting associated with chemotherapy (Benamar 2006).
They are also used as appetite stimulants for treatment of anorexia and HIV-associated
weight loss. In Canada Marinol and Cesamet are used to treat chronic inflammatory
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diseases such as multiple sclerosis and are currently in clinical trials in the U.S. and parts
of Europe (Benamar, 2006).
The immune modulating capabilities of cannabinoids make them a potentially
attractive anti-inflammatory drugs to treat a multitude of diseases. Studies utilizing animal
models of multiple sclerosis, experimental autoimmune encephalomyelitis, and collageninduced arthritis suggest cannabinoids are an effective treatment for a variety of illnesses
(Ramirez, 2005; Sumariwalla, 2004; Wirguin, 1994). Cannabinoids affect a broad
spectrum of immune responses, thereby attacking multiple mechanisms involved in
chronic inflammatory diseases. Studies utilizing LPS as a model for inflammation show
cannabinoids decrease pro-inflammatory cytokine responses and may enhance antiinflammatory cytokine production (Cabral, 2005; Benamar, 2007). Cytokines suppressed
by cannabinoids include those known to regulate cysteine proteases. Cannabinoids inhibit
tumor angiogenesis by decreasing MMP activity (Blazquez, 2003; 2008). MMP and
cathepsins are both upregulated in a multitude of cancers and chronic inflammatory
diseases (Keyszer, 1998). As mentioned before, macrophages are often the primary
producers of cytokines and proteases during inflammatory responses. These studies
combined support the need for investigation on cannabinoid modulation of cysteine
cathepsins in macrophage populations during inflammation, which nothing was known
when this research project began.
Rationale and Objectives
Increased cathepsin expression and activity are associated with rheumatoid arthritis,
multiple sclerosis, atherosclerosis, a multitude of cancers, and other diseases. The
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mechanisms resulting in increased cathepsin activities during these disease processes
remain poorly understood. Infiltrating immune cells producing inflammatory mediators
and cathepsins are thought to be the major cause of tissue destruction in numerous
inflammatory diseases. Among the infiltrating immune cell types, cathepsin expression is
highest within GR-1+/Mac-1+ macrophages. Therefore, this study focuses on
understanding the regulation of cysteine cathepsins in macrophages.
The objective of this study is to elucidate the regulation of cathepsins by TLR and
to investigate the use of cannabinoids as pharmacological therapeutics to alter cathepsins
during an inflammatory response. Signaling through TLR causes cell activation and
release of inflammatory mediators as important defenses against pathogens. Very few
studies have examined the impact of TLR activation on cysteine cathepsins. TLR
signaling could increase cathepsin gene expression, enzymatic activity or decrease gene
expression of endogenous inhibitors. TLR4 signal transduction involves pathways that are
dependent and independent of the MyD88 adaptor molecule. Differential cellular
responses are obtained depending on the signaling pathway activated. Therefore, this
study examines TLR ligands, which are MyD88-dependent and or independent. This study
also investigates the role of inflammatory cytokines produced in response to TLR ligands
in cathepsin regulation.
LPS is the most extensively studied TLR ligand and is a classic model for
inflammation. Cannabinoids modulate a variety of immune responses, including the LPS
response. Little is known about cannabinoids’ impact on macrophage responses to other
TLR ligands. The drugs suppress production of inflammatory mediators, including
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chemokines and cytokines. Cannabinoids may mediate their effects on the immune system
through receptor-dependent or -independent mechanisms. Cannabinoid receptor subtype 1
(CB1) and receptor subtype 2 (CB2) have differential expression in immune cells with the
CB2 receptor being more prevalent. This study investigates the use of cannabinoids to
alter cathepsin activity during the inflammatory response and the involvement of
cannabinoid receptors.
These studies combined will address multiple questions pertaining to the regulation
of cysteine cathepsins. Does macrophage activation by MyD88-dependent and independent TLR ligands affect cysteine cathepsins? Are the changes in cathepsins at the
level of gene expression or enzymatic activity? Are the endogenous inhibitors, cystatins,
affected by cell stimulation with TLR ligands? Are the changes in cathepsins a direct
effect due to TLR signaling cascades and cell activation or indirect effect due to proinflammatory cytokines? Can cannabinoids alter cathepsins during the inflammatory
response? Is this action cannabinoid receptor mediated? The answers to these questions
will provide insight to the regulation of cathepsins during infection and characterize the
mechanisms involved. Furthermore, the studies focusing on cannabinoids may lead to the
use of cannabinoid receptor selective agonists as therapeutic agents for chronic
inflammatory diseases to prevent cathepsin involvement in pathological tissue destruction.
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Chapter 2: Materials and Methods

Mice
Female C3D2F1/J (The Jackson Laboratory, Bar Harbor, ME) were used from 9 to
21 weeks of age. Mice were housed under specific pathogen-free conditions. Research
complied with all relevant laws, guidelines, and policies. Protocols were approved by
IACUC at VCU.
Cell Lines
Culture medium for murine macrophage J774 cell line (American Type Culture
Collection (ATCC), Manassas, VA) was previously described (Harrison, 2003). Murine
macrophage cell line P388D1 (ATTCC) was grown in RPMI 1640 containing 10% heatinactivated fetal bovine serum (FBS) (Biofluids, Rockville, MD) and antibiotics. A
macrophage cell line was generated from bone marrow cells of cannabinoid receptor type 2
deficient (CB2-/-) mice by J2 retroviral infection (Blasi, 1989). CB2-/- cells were cultured
in DMEM containing 10% FBS and antibiotics. Macrophage/microglial cell line EOC 20
derived from C3H/HeJ mice (ATCC) were grown in DMEM containing 10% FBS,
antibiotics and 10% LADMAC (ATCC) conditioned medium as a source of CSF-1.
Monoclonal and Polyclonal Antibodies
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Cell-free culture supernatants from monoclonal antibody-producing rat-mouse
fusion B cell hybridomas (ATCC) produced anti-B220 (clone RA3-3A1), and anti-Thy1.2
(clone J1j.10), anti-CD8 (clone 53-6.72) and anti-FcgII/III receptor (clone 2.4G2).
Monoclonal anti-CD11b (Mac-1; clone M1/70), anti-HSA (clone J11d), anti-B7-1 (clone
1G10), anti-B7-2 (clone GL1), anti-CD11c (clone HL3), anti-ICAM-1 (3E2),
fluoresceinated anti-I-Ek (clone 17-3-3S), anti-CD14 (clone rmC5-3) and fluoresceinated
anti-rat Ig kappa light chain (clone Mrk-1) antibodies were purchased from PharMingen
(San Diego, CA). Monoclonal anti-ICAM-1 (clone KAT-1), anti-CD48 (clone MRC OX78) and fluoresceinated anti-I-Ab,s (clone MRC OX-3) were purchased from Serotec USA
(Washington, DC). Monoclonal anti-TLR4/MD2 (clone MTS510) and anti-TNF-α (clone
TN3-19.12) were purchased from e-Biosciences (San Diego, CA). Monoclonal rat antimouse IL-1β (clone 30311.11 ) was purchased from R&D Systems (Minneapolis, MN).
FITC anti-mouse MHC Class I H-2Kk (clone 36-7-5) was purchased from Biolegend (San
Diego, CA). Mouse IgG technical grade was purchased from Sigma Aldrich Chemical Co.
(St. Louis, MO). Rabbit complement and monoclonal anti-Dec 205 (clone NLDC-145 )
antibody were purchased from Cedarlane (Ontario, CA). Polyclonal fluoresceinated antihamster IgG antibodies and MOPC-104E, were purchased from Jackson ImmunoResearch
Laboratories, Inc. (West Grove, PA) and Cappel Organon Teknika (Durham, NC),
respectively.
Splenocyte Preparation
Spleens were harvested from C3D2F1/J mice and homogenized by hand into a
single-cell suspension. Erythrocytes were removed by hypotonic lysis in Tris-buffered
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ammonium chloride. Nucleated cells were prepared for cathepsin assays and
immunofluorescence staining. For some experiments, splenic macrophages and B cells
were enriched by Ab- and complement-mediated cytolysis as described (Gondre-Lewis,
2003; Hartmann, 2005). Briefly, macrophages were enriched by 30 min incubation of cells
on ice with saturating amounts of anti-B220 and anti-Thy1.2 antibodies followed by 45
min incubation at 37°C with low toxicity rabbit complement. The enriched cells were
cultured for 2 h at 37°C in complete medium, non-adherent cells were removed and
adherent cells were considered the splenic macrophage population. For B cell enrichment
splenocytes were incubated on ice with anti-Thy1.2 for 30 min followed by addition of
rabbit complement as above. The enriched cells were cultured for 2 h 37°C in complete
medium, and non-adherent cells were collected as the B cell population.
Cathepsin Substrates and Inhibitors
Respective Magic Red TM (MR) substrates (Immunochemistry Technologies, LLC,
Bloomington, MN) for Cat B, L and S were Z-Arg-Arg-MR-Arg-Arg, Z-Phe-Arg-MRArg-Phe, and Z-Val-Val-Arg-MR-Arg, respectively. General cysteine cathepsin inhibitor
was E-64d (Peptide International, Inc., Louisville, KY), and selective inhibitors for Cat L
and S were Z-Phe-Phe-CHN2 and Z-Val-Val-Nle-CHN2, respectively (Bachem Bioscience,
Inc, King of Prussia, PA). Respective 7-aminomethyl-coumarin (AMC) substrates
(Bachem Bioscience) for Cat B, L and S were Z-Arg-Arg-AMC, Z-Phe-Arg-AMC, and ZVal-Val-Arg-AMC. Stock solutions of substrates and inhibitors in DMSO were stored at 80°C.
Confocal Microscopy
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Macrophages at 5 x 105 were plated in Lab-Tek chambered coverglass plates (Nunc
Inc. Naperville, IL) in phenol red-free complete DMEM. Cells were incubated with 500
nM LysoTracker DND-26, an acidic vesicle marker, (Molecular Probes, Eugene, OR) for 1
h at 37°C followed by addition of 1 µM Cat L MR-conjugated substrate for 15 min.
Intracellular red fluorescent hydrolyzed product from Cat L substrate and green
LysoTracker DND-26 were detected with a Zeiss LSM 510 Meta confocal microscope
(VCU Imaging and Flow Cytometry Core Facility) using dual excitation wavelengths of
488 and 543 nm.
Cathepsin Enzymatic Activity in Live Cells Using Magic Red Substrates
Spleen cell suspensions with erythrocyte hypotonic lysis were prepared or J774
macrophage cell line was utilized. For initial assays, cells at 4 x 106 cells /ml in PBS, or
RPMI 1640 containing 5% heat-inactivated FBS, L-glutamine, 2-ME and antibiotics were
incubated with or without various substrate concentrations for 1 h at 37°C in 5% CO2humidified atmosphere. Substrate concentrations for subsequent experiments were 6 µM
for Cat B and Cat L and 24 µM for Cat S. For time course experiments, cells were
incubated with substrate from 15 min to 3 h, and a 45-min incubation was selected for all
subsequent assays. Cells were washed twice with PBS containing 0.02% sodium azide to
remove excess substrate, and in some experiments, cells were fixed with 0.5%
paraformaldehyde in PBS before analysis. Red fluorescence intensity of cells was
measured with logarithmic amplification using a Becton Dickinson FACScan equipped
with a 15 mW 488 nm argon laser and appropriate excitation filters (BD Biosciences, San
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Jose, CA). Data on 20,000 splenocytes and macrophage cell lines were collected, and
forward-angle side scatter gates were set to exclude dead cells and cell clumps.
Compensations were set to remove green emission due to uncleaved substrate.
Substrate in Stimulated Cells Not Limiting
Macrophages at 2 x 106 cells/well were cultured in complete medium in 6-well
culture dishes with or without 10 µg/ml LPS for 48 h. Cells were harvested, washed twice
in PBS and cathepsin activities were assessed using MR-conjugated cathepsin substrates as
described above or cell lysate assays were performed as described below.
Protease Activity in Cell Lysates
Cathepsin activities in cell lysates were measured as described with modifications
(9,10). Lysates were prepared in 0.75% Triton X-100 lysis buffer at 1 x 108 cells/ml.
Protein concentration in the lysates was measured by bicinchoninic acid assay. Cat B and
L were activated by incubation at 37°C for 15 min before substrate addition. Cat S
activation time was 1 h at 37°C. Reactions contained 6.25 µg protein for Cat B and L, and
25 µg protein for Cat S assay. Activation buffer for Cat B was 87.7 mM KH2PO4 /12.3
mM NaHPO4 containing 4 mM EDTA, pH 6 and 2.6 mM dithiothreitol (DTT). Cat B
activity was measured by cleavage of 5 µM AMC selective Cat B substrate for 2 h.
Activation buffer for Cat L was 340 mM Na acetate/60 mM acetic acid containing 4 mM
EDTA, pH 5.5 and 1.3 mM DTT. Cat L activity was assessed by cleavage of 6.6 µM
AMC Cat L selective substrate for 1 h. Activation buffer for Cat S was 0.1 mM KH2PO4
containing 5mM EDTA, pH 7.5 and 5 mM DTT. Cat S activity was measured by cleavage
of 10 µM AMC selective Cat S substrate for 3 h. Reactions were stopped by 1mM
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iodoacetamide (Sigma). Background controls were reactions lacking cell lysate.
Fluorescence was measured by a Shimadzu spectrofluorophotometer RF5000 (Columbia,
MD) with an excitation wavelength of 370 nm and emission wavelength of 460 nm. One
activity unit is 1.0 fluorescence unit per cell.
MR Substrate Specificity
For specificity experiments, spleen cells at 4 x 106/ml were pre-incubated with 0.45
mM E-64d for 3 h, 0.14 mM Z-Phe-Phe-CHN2 or 0.95 mM Z-Val-Val-Nle-CHN2 for 30
min before addition of substrate. Control cells were incubated with the corresponding
DMSO concentration, which was 2.3% for E-64d and 3.5% for selective inhibitor assays.
To detect viable cells, 10 nM carboxyfluorescein diacetate, acetoxymethyl ester (5-CFDA,
AM), a cell viability marker, (Molecular Probes) in DMSO/PBS was added at the time of
substrate addition. Substrate concentrations were increased to 8.3 µM for Cat B and 10
µM for Cat L to enhance detection sensitivity, when substrates were used in conjunction
with 5-CFDA,AM. Green and red fluorescence intensities of cells were measured with
logarithmic amplification using a Becton Dickinson FACScan as described above. For
assays with inhibitors, two-color flow cytometry (FCM) was performed with
compensations to eliminate emission spectral overlap of 5-CFDA, AM and cresyl violet.
Compensation settings on the FACScan were determined by analyzing single-stained cells.
Histograms represent red fluorescence intensity of green 5-CFDA, AM+ viable cells.
Cathepsin Activity in Live Cells Using AMC Substrates
For initial experiments, macrophages at 4 x 106 cells/ml in PBS were incubated
with or without a cathepsin inhibitor under conditions described above. Cells were washed
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twice in PBS to remove excess inhibitor and resuspended in PBS and incubated with 10
µM of AMC selective Cat B, L or S substrate for 1 h at 37°C. Fluorescence was measured
by a spectrofluorophotometer as described above. One activity unit is 1.0 fluorescence unit
per cell. Background controls were cells incubated with the corresponding DMSO
concentration but without a cathepsin substrate. Percent inhibition was calculated as [1(fluorescence units without inhibitor – fluorescence units with inhibitor) / fluorescence
units with inhibitor] x 100%. For subsequent experiments utilizing AMC-conjugated
substrates with live cells at 1 x 106 cells/ml were incubated in PBS with 10 µM of AMC
selective Cat B, L or S substrate for 1 h at 37°C. As above fluorescence was measured by a
spectrofluorophotometer. Fold increase values were calculated by dividing fluorescent
values of treated cells by values for medium control cells.
Cathepsin Assays Combined with Immunofluorescence Staining
Single cell suspensions of splenocytes were prepared as described above. In some
cases, macrophages and B cells were enriched using Ab- and complement-mediated
cytolysis as described above. Spleen cells were incubated with substrate and washed. Cells
were then incubated with 1 µg of monoclonal anti-B220, anti-Thy-1.2, or 3 µg of antiMac-1 Ab along with 25 µg of mouse of IgG to block Fc receptors for 30 min at 4°C, and
washed in PBS containing 0.1% BSA and 0.02% sodium azide. Cells were then incubated
with 0.5 µg of fluoresceinated monoclonal anti-rat kappa Ab for 30 min at 4°C, washed
twice in PBS containing 0.02% sodium azide and fixed in 0.5% paraformaldehyde.
Fluorescence intensity with logarithmic amplification was measured by a Becton
Dickinson FACScan as described above. Fluorescence intensity of cells for two-color
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analysis was measured by FCM, and compensations were set to eliminate emission spectral
overlap of fluorescein and cresyl violet. Analysis of cathepsin activity in splenocyte
subpopulations was performed with gating on Mac1+, B220+, and Thy1.2+ cells.
TLR Ligands
Bacterial lipopolysaccharide (LPS) from E. coli 055:B5, peptidoglycan (PGN) from
S. aureus, and polyinosinic-polycytidylic acid sodium salt (Poly I:C) were purchased from
Sigma-Aldrich (St. Louis, MO). Formalin-killed Corynebacterium parvum (C. parvum)
was purchased from Biotechnology Limited (Beckenham, England).
TLR Stimulation
For initial experiments, macrophage cell lines at 2 x 106 cells/well were cultured in
complete medium with various doses of LPS, PGN, Poly I:C or C. parvum at 37°C for time
points ranging from 12 to 48 h. Cells were harvested, washed in PBS and protease activity
of cathepsins was assessed using FCM or spectrofluorophotometry as described above.
For subsequent experiments, 2 x 106 P388D1, EOC 20 or CB2-/- cells were incubated
without or with 1 µg/ml LPS, 4 µg/ml PGN, 10 µg/ml Poly I:C, C. parvum or complete
medium for 6, 24 or 48 h as indicated. Cells were harvested and washed twice in PBS, and
cell viability was assessed by trypan blue exclusion. Live cell cathepsin assays using MRor AMC-conjugated substrates were performed as described above. Cell-free culture
supernatants were collected or RNA was isolated as described below.
ImageStream® Cell Analysis
Cells were incubated without or with 1 µg/ml LPS for 24 h and harvested as above.
Cells at 1 x 106 cells/ml in PBS were incubated with 6 µM Cat L or B substrate or 15µM
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Cat S substrate for 45 min. Cells were then incubated with 100 nM LysoTracker DND-26
for 15 min and analyzed using ImageStream® Cell Analysis System (Amnis Corporation,
Seattle, WA) courtesy of Amnis Corporation and University of Virginia, School of
Medicine FCM Core Facility. Analysis and similarity bright detail scores were performed
in collaboration with Dr. Philip Morrissey at Amnis Corporation, as previously described
(Beuma, 2006). Similarity bright detail is based on identification of the small puntate
staining in a pair of images. The value is based on how well fluorescence due to
LysoTracker DND-26 in channel 3 correlates with MR fluorescence in channel 5.
Cathepsin Secretion
CB2-/- macrophages at 4 x 106 cells per well were cultured with and without LPS or
10 mM NH4Cl/mannose-6-phosphate in phenol red-free DMEM containing 10% FBS and
supplements at 37°C for 24 h. Cell-free culture supernatants were collected and
centrifuged through Centricon-30 microconcentrators (Amicon, Beverly, MA) at 2000g for
30 min. Cell number and viability for each treatment was assessed using trypan blue
exclusion. Protein concentration in concentrated supernatants was measured by
bicinchoninic acid assay. Cathepsin activity in culture supernatants was measured
according to protocols for cellular lysates as described above. Cathepsin activities were
measured by cleavage of 5 µM selective Cat B AMC-substrate for 2 h, 6.6 µM Cat L
selective AMC-substrate for 1 h, and 10 µM selective Cat S AMC-substrate for 3 h.
Background controls were reactions containing phenol red-free DMEM containing 10%
FBS. Fluorescence was measured by a spectrofluorophotometer RF5000 as above. Data
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values are expressed as secreted activity per cell, which was calculated as fluorescence
units/total cell number per culture.
Semiquantitative Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)
RNA was isolated using Trizol reagent (Invitrogen). Cat B primers (forward
primer: 5′-TGC TTA CTT GCT GTG GCA TC-3′; reverse primer: 5′-GGG AGT AGC
CAG CTT CAC AG-3′), Cat L primers (forward primer: 5′- CCC CAA GTC TGT GGA
CTG GAG AGA-3′; reverse primer: 5′-TTT ACA AGA TCC GTC CTT TGC TTC-3′),
Cat S primers (forward primer: 5′-TAA TCG GAC ATT GCC TGA CA-3′; reverse primer:
5′-CTG GAA AGC TTC GGT CAT GT-3′), cystatin B primers (forward primer: 5′-GTC
CCA GCT TGA ATC GAA AG-3′; reverse primer: 5′-GGG TCA AAG GCT TGT TTT
CA-3′), cystain C primers (forward primer: 5′-TCG CTG TGA GCG AGT ACA AC-3′;
reverse primer: 5′-ATC TGG AAG GAG CAG AGT GC-3′), CB1 receptor primers
(forward primer: 5′- GCT TGC GAT CAT GGT GTA TG-3’; reverser primer: 5’-CAT
GCT GGC TGT GTT ATT GG-3’), CB2 receptor primers (forward primer: 5′- ATG TAC
CCA CCT TGG CTG AG-3’; reverser primer: 5′- ACC TTG GGC CTT CTT CTT TC-3’
), β-actin primers (forward primer: 5′-ATC TAG AGG GCT ATG CTC TCC-3′; reverse
primers: 5′-TCT GCA TCC TGT CAG CAA TGC C-3′) were synthesized and purified by
the Virginia Commonwealth University DNA core laboratory (Richmond, VA). Cat B, L
and S primers produce a 237-bp product from bases 447-683, a 294-bp product from bases
410-704, and a 241-bp product from bases 357-597 respectively. Cystatin B primers
produce a 174-bp product from bases 74-244 and cystatin C primers produce a 217-bp
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product from bases 146-362. CB1 receptor, CB2 receptor and β-actin primers produce a
250-bp product from bases 1079-1328, a 355-bp product from bases 655-1009, and a 451bp product from bases 415-865 respectively. RNA at 1µg was treated with amplification
grade DNase I (Invitrogen, Carlsbad, CA) for 20 min at room temperature to remove
genomic DNA. Yield was determined by absorbance at 260 nm, and purity was verified
by 260:280 and 260:230 nm absorbance ratios. RNA was reversed transcribed with
Superscript™ first strand synthesis kit (Invitrogen) using oligo-dT primers according to
manufacturer’s directions. Controls omitted reverse transcriptase to verify that genomic
DNA was not amplified by PCR. Products were amplified by PCR using Platinum Taq
DNA polymerase (Invitrogen). Following initial denaturizing at 94°C for 2 min, samples
were denatured at 94°C for 30 s, annealed at 55°C for 30 s and extended at 72°C for 30 s.
Each cDNA was amplified separately up to 44 cycles. PCR products were separated by
agarose gel electrophoresis. Gels were stained with ethidium bromide, and bands were
visualized by a UV transilluminator with a CCD camera. Band intensities were determined
by AlphaEase FluorChem 8900 (Alpha Innotech Corporation, San Leandro, CA). Relative
expression for each sample was calculated by dividing the intensity of the target band by
the β-actin band intensity.
Co-culture Experiments
Co-cultures were 1 x 106 P388D1 and 1 x 106 EOC 20 cells in complete RPMI
with or without 1 µg/ml LPS at 37°C for 24 h. Single cell type control cultures had 2 x 106
cells per well in medium with or without 1 µg/ml LPS. Cells were harvested and washed in
PBS, and flow cytometric cathepsin assays and immunofluorescence staining were
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performed as described above. Cells were incubated with 25 µg of mouse IgG to block Fc
receptors and 0.25 µg of FITC-conjugated anti-H-2Kk antibody to detect EOC 20 cells.
Fluorescence intensity was measured by a Becton Dickinson FACScan as described above.
Red fluorescence intensities of EOC 20 cells in medium control and LPS-stimulated cocultures were compared with gating on H-2Kk+ cells. Cells negative for H-2Kk were
analyzed for red fluorescence to measure cathepsin activity in the P388D1 macrophage
population.
Activation of Non-responsive Bystander Cells with Culture Supernatants
P388D1 cells at 2 x 106 cells per well were cultured in complete RPMI without or
with 1µg/ml LPS, and cell-free culture supernatants from medium control and LPSstimulated cultures were collected at 6 or 24 h. Cell-free culture supernatants were
concentrated with Centricon-10 microconcentrators (Amicon) and filter sterilized using 0.2
µm low protein binding syringe filters. EOC 20 cells at 2 x 106 cells per well were
cultured in 2.5 ml of conditioned DMEM and 0.5 ml of concentrated culture supernatants
at 37°C for 24 h. Cells were harvested and washed, and cathepsin activities in EOC 20
cells were assessed using AMC-conjugated substrates as described above. Fold increase
was calculated by dividing fluorescence values for LPS-stimulated culture supernatants by
the values for medium control supernatants.
Cytokine Neutralization Studies
As above, P388D1 cells were stimulated with 1µg/ml LPS, and cell-free culture
supernatants from medium control and LPS-stimulated cultures were collected at 6 h.
Cell-free culture supernatants were concentrated and filter sterilized as described above.
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Concentrated culture supernatants were then incubated on ice for 1 h with 0.75 to 3 µg/ml
anti-TNF-α, 5 to 20 µg/ml anti-IL-1β mAb, or 3 µg/ml or 20 µg/ml of mouse IgG as
corresponding controls. EOC 20 cells at 2 x 106 cells per well were cultured in 2 ml of
conditioned DMEM and 1 ml of antibody-treated culture supernatants at 37°C for 24 h.
EOC 20 cells were harvested, washed and assayed for cathepsin activity in live cells using
AMC-conjugated substrates as described above.
Cannabinoid Receptor Expression
LPS stimulation of P388D1 or CB2-/- macrophages was performed as described
above. Cells were harvested and washed, and RNA was isolated using Trizol reagent
(Invitrogen). Semiquantitative RT-PCR was performed as described above.
Cannabinoid Treatment of Cells
THC and CP-55,940 (VCU Center for Drug Abuse Research) were prepared in
ethanol as described (McCoy, 1995). Vehicle was 0.1% ethanol as in final drug
preparations. P388D1 or CB2-/- cells at 2 x 106 cells per well were pre-incubated with
THC, CP-55,940 or vehicle for 4-h and then stimulated with 1 µg/ml LPS for another 24 or
48 h. Cells were harvested and washed, and viability was determined by trypan exclusion.
Cathepsin activities were assessed using AMC-conjugated substrates as described before.
Characterization of CB2-/- Macrophages
Immunofluorescence staining of CB2-/- BM cells was performed by Constance
Hartmann and Mika Shima (VCU). CB2-/- BM cells were stained as described (Clements
et al., 1996). Briefly, cells were co-incubated with 25 mg of mouse IgG to block Fcγ
receptors. Cells were incubated with a saturating amount of monoclonal antibody followed
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by the appropriate fluoresceinated secondary antibody. Controls for nonspecific
fluorescence were cells incubated with irrelevant species- and isotype-matched antibody
(MOPC 104E, 53-6.72 or hamster IgG), followed by the appropriate fluoresceinated
secondary antibody. For MHC class II expression, cells were incubated with
fluoresceinated MRC OX-3 or irrelevant 17-3-3S. Fluorescence intensity was measured as
described above.
Apoptosis Studies
P388D1 macrophages at 2 x 106 cells per well in complete medium were incubated
with vehicle or THC at 37°C for 18 h. Apoptotic cells were detected by annexin V binding
to phosphatidylserine using an annexin V-FITC apoptosis detection kit (BD Pharmingen,
San Diego, CA). Harvested cells were washed, and 5 x 105 cells were resuspended in 200
µl of binding buffer followed by addition of 0.25 µg of FITC annexin-V. Cells were
incubated at room temperature for 15 min. Excess FITC annexin-V was removed by
centrifugation, and cells were resuspended in 800 µl of binding buffer and analyzed by
FACSCAN as described above. Propidium iodide was added to cell samples immediately
before flow cytometric analysis. These studies were performed by Constance Hartmann.
TLR Cell Surface Expression
P388D1 macrophages at 2 x 106 cells per well were cultured in complete medium
with vehicle or THC for 4 h. Cells were harvested, washed and incubated on ice for 30 min
with 3 µg FITC-conjugated anti-TLR-4/MD2, 2µg FITC-conjugated anti-CD14, or
controls were incubated with 0.5 µg of fluoresceinated monoclonal anti-rat kappa Ab.
Cells were washed twice in PBS containing 0.02% sodium azide and fixed in 0.5%
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paraformaldehyde. Fluorescence intensity with logarithmic amplification was measured by
a Becton Dickinson FACScan as described above.
Statistical Analyses
Parametric analysis of variance was performed by two-tailed Student’s t test. TLR
ligand-treated or inhibitor-treated groups were compared with medium or DMSO controls,
and P values < 0.05 were considered significant. Mean fluorescence intensities (MFI) of
cell subpopulations gated by cell surface marker expression were compared, and P values
< 0.05 were considered significant. Comparisons between THC experimental samples and
controls were made by Dunnett’s t test.
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Chapter 3: New Assay Staining to Measure Cysteine Cathepsin
Activity in Live Cells

Introduction
During the past few years, cysteine cathepsins are being proposed as candidate
disease markers. Increased levels of Cat B, L and S are associated with various
inflammatory myopathies and cancers therefore this study focused on these three
proteases (Berdowska, 2004). This correlation has led to the possibility that cathepsins
could serve as useful diagnostic and prognostic markers of disease. In previous studies,
reverse transcriptase-PCR (RT-PCR) or Western blot analysis are utilized to assess
mRNA and protein expression of cathepsins. RT-PCR determines a change in gene
expression but does not indicate the amount of translated cathepsin. Western blot
analysis performed with cell lysates requires a high number of cells and is a time
consuming technique. Although these methods are good indicators of expression, they
do not render any information about enzymatic activity. Enzyme-linked
immunosorbent assay (ELISA) technology measures the amount of cathepsins in serum
or extracellular fluid. Antibodies typically used for this technique and western blot
analysis recognize both precursor and mature forms of cathepsins. Procathepsins lack
enzymatic activity (Berdowska, 2004; Turk, 2001), and their presence in serum or
extracellular fluid may be irrelevant. Secreted mature cathepsins may be bound by
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endogenous inhibitors, which also cannot be distinguished using this method. Lysate
enzymatic assays are typically employed to measure cathepsin activity through the use
of selective substrates attached to a fluorogenic molecule. These assays require an
activation step (Barrett, 1981), which could drive procathepsin to mature cathepsin
(Berdowska, 2004; Turk, 2001), and, therefore, may not be accurate of what is present
in live cells. A recent approach uses activity-based probes for determination of active
intracellular cathepsins in intact cells (Falgueyret, 2004; Lennon-Deménil, 2002). The
fluorescent or radiolabeled probes bind active sites of the enzymes, and their binding
affinity is then measured in cell lysates, which requires a high number of cells. Each of
these techniques has advantages and disadvantages. All these methods measure a
parameter as an average of a cell population and require cell purification to evaluate
individual cell types within a heterogeneous cell population.
To be a useful disease marker, clinical diagnostic and prognostic tests
necessitate sensitive, accurate and reliable assays with high-throughput capacity. This
study investigated a novel method for measuring cathepsin activity on a per cell basis
inside cells that have been immunofluorescence stained for cell surface molecules.
Enzymatic activity of cathepsins in intact cells was assessed through FCM using
selective fluorogenic peptide substrates. The fluorophore cresyl violet is bi-substituted
with peptide sequence selective for a particular cathepsin (Boonacker, 2001). When
enzymatic cleavage occurs at one or both sites, a peptide is released, and red
fluorescence can be measured (Boonacker, 2001). These substrates have been mainly
used for confocal microscopy with live cells due to the fluorophore’s emission spectral
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properties (Figure 3) (Boonacker, 2001; Du, 1998). This new approach utilizes these
substrates for single argon laser flow cytometers. Cathepsin activities were measured on
a per cell basis in murine macrophage J774 cell line and spleen cells. Selectivity of
substrate cleavage was confirmed with cysteine cathepsin inhibitors. The activity assay
was combined with immunofluorescence staining for cell surface molecules to assess
cathepsin activities in a heterogeneous leukocyte population. Thus, this novel assay
would be an important advance for assessing cathepsin activities in cells from patients
with related diseases and disorders.
Results
Titration of Cathepsin Substrates
Cresyl violet-conjugated peptide substrates are cell permeable and very quickly
enter live cells (Falgueyret, 2004). Cat B selectively cleaves the Z-Arg-Arg substrate
under acidic conditions (Barrett, 1981), whereas Z-Phe-Arg and Z-Val-Val-Arg
substrates are preferentially cleaved by Cat L and S, respectively (Barrett, 1981;
Kinschke, 1994). First, the substrates were utilized for confocal microscopy (Figure 3).
Red fluorescent product generated from the Cat L substrate localized within vesicular
structures as indicated by punctate cytoplasmic fluorescence. These cytoplasmic
vesicles were acidic based on co-localization with a green fluorescent acidotropic probe.
Similar results were observed with Cat B and S substrates (data not shown).
I examined the usefulness of these substrates for measuring proteolytic activity
inside cells by FCM. When excited at 488 nm, cresyl violet-conjugated substrates emit
fluorescence with maximal emission in the green FL-1 channel with minimal emission
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DIC

Cat L

Lysotracker DND-26

Overlay

Figure 3. Localization of Cat L activity inside a macrophage cell line.
Top left panel shows differential interference contrast (DIC) of labeled cells.
Intracellular red fluorescent hydrolyzed product from Cat L substrate and green
LysoTracker DND-26 were detected with a Zeiss LSM 510 Meta confocal microscope
using dual excitation wavelengths of 488 and 543 nm. Co-localization is indicated by
yellow fluorescence.
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in the red FL-3 channel (Falgueyret, 2004). Once the peptide is removed, fluorescence
shifts to longer wavelengths, and the highly fluorescent leaving group has maximal
emission in the red FL-3 channel (Falgueyret, 2004). Compensations were set to remove
signals in the green channel due to uncleaved substrate as described in Chapter 2. Analysis
of cathepsin activity in a macrophage cell line performed with and without compensation
revealed that the compensation settings did not alter the red fluorescence of the product
(data not shown). Optimal substrate concentrations were determined by serial dilutions of
each substrate for both murine spleen cells and macrophage cell line. Assays were
performed in PBS and medium, and mean fluorescence intensities (MFI) were compared.
Cells incubated with substrates in medium had slightly lower fluorescence intensity
compared to those in PBS (data not shown), although this was not significantly different.
Cat S substrate concentrations ranged from 6 µM to 36 µM (Figure 4A), and fluorescence
profiles displayed unimodal distribution. Red fluorescence intensity, which measured
product formation, shifted to higher values with increasing substrate concentrations, and
maximal signal was achieved at 24 µM. In contrast, green fluorescence intensity from the
uncleaved substrate did not change (data not shown). Cat B activity was assayed using
substrate concentrations from 0.4 µM to 40 µM, and 6 µM was selected for subsequent
experiments (data not shown). Cat L activity was assessed in spleen cells with substrate
concentrations ranging from 1.8 µM to 36 µM (data not shown) and in macrophage cell
line J774 with substrate concentrations ranging from 1.8 µM to 6 µM (Figure 4B). Cells
incubated in the absence of substrate had a MFI of 3.8, and, again, fluorescence intensity
increased with higher substrate concentrations. Cat L substrate at 6 µM was used in
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Figure 4. Optimal cathepsin substrate concentrations and time course of product
formation.
Cells were incubated with the indicated substrate concentrations at 37°C for 1 h, washed,
and red fluorescence intensity (FL3-H) was measured by FCM. Counts are number of
cells per channel. (A) Cat S activity in murine spleen cells. (B) Cat L activity in J774
macrophage cell line. Negative denotes cells incubated without substrate. (C and D)
Spleen cells were incubated with 6 µM Cat L substrate at 37°C for the indicated time
periods, washed, and analyzed by FCM. Histograms are representative of 3 separate
experiments. Reproduced with copyright permission.
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subsequent assays.
Time Course of Product Formation and Evaluation of Product Leakage
I also determined the time kinetics of product formation, and evaluated the
possibility that the fluorescent product may leak from cells. Separate spleen cell samples
were incubated with Cat L substrate for 15 to 75 min. At each time point, cells were
washed twice in PBS, fixed, and analyzed by FCM. At 15 min, the MFI was 29 and
increased to 44 by 45 min (Figure 4C). At 75 min, the MFI was 40, which was not
significantly different from that at 45 min. Similar results were observed for Cat B activity
(data not shown). A 45-min incubation was utilized for all following assays. In a separate
experiment, the incubation time period was extended to 3 h to detect any major changes of
the cresyl violet product in cells. Cells incubated with Cat L substrate from 1 to 3 h had
MFI values of 25 that did not change (Figure 4D). Analogous findings were also seen for
Cat B activity (data not shown). No significant product loss from cells was detected
indicating that additional incubation time required for immunofluorescence staining would
not affect measurements of cathepsin activity.
Increased Cathepsin Activity in LPS-Stimulated Macrophages
The macrophage cell line was stimulated with LPS for 48 h, and then assayed for
Cat B, L and S activities (Table 3). Fluorescent profiles of LPS-stimulated macrophages
shifted to higher values for all the cathepsins. LPS treatment caused a significant increase
in red MFI of cells for Cat B, L, and S, indicating that the substrates were not limiting.
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Table 3
Comparison of flow cytometer and cell lysate assays.
Fold Increase (LPS vs. Medium)
Cathepsin

Flow Cytometer Assay

Cell Lysate Assay

B

2.00 ± 0.90*

4.28 ± 1.56**

L

2.48 ± 0.96**

4.56 ± 1.91***

S

3.28 ± 1.14*

3.51 ± 0.58***

Macrophages were stimulated with 10 µg/ml of LPS for 48 h. Indicated cathepsin
activities were assayed in cells with MR substrates by FCM, or in cell lysates with AMC
substrates. Data represent the mean ± SD from 3 or more separate experiments. Fold
increase was calculated by dividing the fluorescence measurements for LPS-stimulated
cells by the values for medium control cells. LPS vs. medium: *P < 0.05; **P < 0.01; ***;
P < 0.0001. Reproduced with copyright permission.
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Similar results were obtained when these cathepsin activities in cell lysates were assayed
using AMC substrates. Substrates for the cell lysate assay have the same amino acid target
sequence as the MR substrates, but the leaving group was AMC. Analogously, proteolytic
activities of Cat B, L, and S within cellular lysates were significantly increased after LPS
stimulation (Table 3). Enzymatic activity of all three cathepsins was significantly higher in
LPS-stimulated cells compared to medium control cells using both assays.
Comparison of Product Fluorescence in Live and Post-Fixed Spleen Cells
Fluorescent product values for Cat B, L and S in cells post-fixed with 0.5%
paraformaldehyde were compared to those for live cells. Spleen cells were incubated with
MR Cathepsin substrates, washed twice and either analyzed as live cells in PBS or fixed in
paraformaldehyde before analysis. When Cat B product fluorescence was evaluated in live
cells the MFI was 24, almost half that in post-fixed cells with a MFI of 42 (Figure 5A).
No significant difference for fluorescence values between live and post-fixed cells was
observed for Cat L and S (Figure 5B) and C). In the absence of substrate, there was no
difference in red autofluorescence between live cells and fixed cells, both having MFI
values of 1.6 (Figure 5A). Fixed cells stored in a refrigerator for 14 days also had no
significant decrease in red product fluorescence intensity (data not shown). Fluorescent
products did not diffuse out of post-fixed cells, indicating cell fixation after
immunofluorescence staining would not underestimate cathepsin activities.
Selectivity of Cathepsin Assays
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Figure 5. Cathepsin activities in viable and post-fixed spleen cells.
Viable spleen cells in duplicate were incubated for 45 min with or without cathepsin
substrate. Cells were washed and analyzed as live cells. Cells in parallel were washed and
then fixed in paraformaldehyde before analysis. (A) Cells incubated with or without 6 µM
Cat B substrate. Lv Neg denotes negative control of live cells. Fx Neg denotes negative
control of fixed cells. (B) Cells incubated with 6 µM Cat L or (C) 24 µM Cat S substrates.
Reproduced with copyright permission.
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Although the MR substrates have the same peptide sequences as those utilized for
cell lysate assays, reaction conditions with cell lysates are manipulated to favor cysteine
cathepsin activity (Barrett, 1981; Kinschke, 1994), which is impossible to do with viable
cells. Selectivity of the assays, in addition to the amino acid target sequence of the
substrates was further assessed by pre-incubating spleen cells with cell permeable cysteine
cathepsin inhibitors before substrate addition. Splenocytes were sensitive to the toxicity of
inhibitors, especially the Cat L selective inhibitor. Due to the splenocyte sensitivity, 5CFDA, AM was used as a cell viability marker. 5-CFDA, AM and cathepsin substrates
were incubated for an additional 30 min after pre-incubation with the indicated inhibitor.
All cells were washed twice and suspended in PBS for analysis as live cells. Analysis was
performed on green fluorescent 5-CFDA, AM+ viable cells, and cell viability was ≥ 70% in
the representative experiments shown in Figure 6. Spleen cells were incubated with E64d, a general cysteine cathepsin inhibitor (Barrett, 1981), before addition of Cat B
substrate and 5-CFDA, AM. Pre-treatment of cells with E-64d decreased red MFI by 37%
compared with cells incubated with the substrate alone (Figure 6A). Similarly, cells were
incubated with Cat L selective inhibitor, Z-Phe-Phe-CHN2 prior to substrate addition
(Kinaschke, 1994). This inhibitor diminished MFI by 44% (Figure 6B). Likewise, Cat S
selective inhibitor, Z-Val-Val-Nle-CHN2 (Shaw, 1993), decreased MFI by 65% (Figure
6C). Higher inhibitor concentrations caused substantial cell death (< 60% viable cells) and
were excluded from analysis.
To confirm the selectivity of the cathepsin assays, inhibitors were utilized in
conjunction with non-corresponding substrates. Cat L selective inhibitor marginally
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Figure 6. Selectivity of cathepsin assays.
Spleen cells were incubated without or with a cysteine cathepsin inhibitor, and then with a
cathepsin substrate and cell viability marker 5-CFDA, AM for an additional 45 min. Cells
were washed and analyzed by FCM. Graphs are the product fluorescence profiles of viable
5-CFDA, AM+ cells. (A) Pre-incubation for 3 h without and with E-64d followed by Cat B
substrate. (B) Incubation for 30 min without and with Z-Phe-Phe-CHN2 and then with Cat
L substrate. (C) Pre-incubation for 30 min without and with Z-Val-Val-Nle-CHN2
followed by Cat S substrate. (D) Pre-incubation without or with Cat L selective inhibitor
Z-Phe-Phe-CHN2 followed by Cat B selective substrate. (E) Pre-incubation without or
with Cat L selective inhibitor followed by Cat S selective substrate. (F) Pre-incubation
without or with Cat S selective inhibitor Z-Val-Val-Nle-CHN2 followed by Cat B selective
substrate. (G) Pre-incubation without or with Cat S selective inhibitor followed by Cat L
selective substrate. (H) Macrophage cell line was incubated with or without the indicated
inhibitor (Inhib), followed by a selective cathepsin substrate conjugated to AMC.
Fluorescence was measured with a spectrofluorophotometer. Percent inhibition was
calculated as described in Chapter 2. Values are the mean ± SD from three separate
experiments. * Cells with inhibitor vs. cells without inhibitor: P < 0.01. Reproduced with
copyright permission.
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affected the MFI of cells incubated with Cat B and S substrates (2.5% and 19% decrease,
respectively) (Figure 6D and E), in contrast with Cat L substrate (see Figure 6B). Cat S
selective inhibitor did not diminish MFI of cells using Cat B and L substrates (Figure 6F
and G), unlike the results with Cat S substrate (see Figure 6C). Nonspecific substrate
cleavage appeared to be minimal.
Because the inhibitors did not completely decrease MFI to background MFI of cells
incubated without substrate, cathepsin activity in a viable macrophage cell line was
assessed using AMC conjugated substrates and fluorescence was measured using a
spectrofluorophotometer. Cells pre-incubated with E-64d had a 26% reduction in
fluorescence units for Cat B activity (Figure 6H). Cat L activity dropped by 41% in cells
pre-incubated with the Cat L inhibitor. The Cat S selective inhibitor decreased fluorescent
product formation by 61% (Figure 6H). These results parallel those observed for the MR
substrates including the rank order of the degree of inhibition.
Cathepsin Assay Combined with Immunofluorescence Staining
Cathepsin activity in splenic cell subpopulations was evaluated using
immunofluorescence staining with two-color flow cytometric analysis. mAb recognizing
cell lineage-specific molecules were employed to distinguish three cell types. Spleen cells
were incubated with a Cat Substrate followed by immunofluorescence staining. Figure 7
illustrates representative contour plots. Although all nucleated splenocytes had cathepsin
activities, Mac-1+ macrophages, B220+ B cells and Thy1.2+ T cells were easily identified.
Incubation of spleen cells with the substrates did not change the percentages of the three
cell types based on immunofluorescence staining (data not shown). Cells positively
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Figure 7. Cathepsin assays combined with immunofluorescence staining compared to
cathepsin assays of purified cells.
Spleen cells were incubated with a cathepsin substrate, followed by immunofluorescence
staining for cell lineage-specific cell surface molecules. Contour plots were generated by
two-color FCM. (A) Cat B activity (FL3-H) vs. Mac-1 expression (FL1-H). (B) Cat L
activity (FL3-H) vs. B220 expression (FL1-H). (C) Cat S activity (FL3-H) vs. Thy1.2
expression (FL1-H). Boxes designate cells expressing the respective cell surface
molecules. (D) Cat L activity in purified splenic macrophages vs. gated Mac1+ cells from
unpurified spleen cells. (E) Cat L activity in purified splenic B cells vs. gated B220+ cells
from unpurified spleen cells. Reproduced with copyright permission.
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staining for these molecules as denoted by boxes in Figure 7 were analyzed for the
fluorescent cleavage product (Table 4). MFI for Cat B, L and S activities did not
significantly differ between Mac1+ cells and B220+ cells, however B220+ cells had a trend
of lower values. Thy1.2+ cells had significantly lower MFI values for all three cathepsins
when compared to Mac1+ cells.
To assess whether immunofluorescence staining influenced product fluorescence,
splenic macrophages and B cells were purified by negative selection using Ab- and
complement-mediated cytolysis and assayed for cathepsin activities. Fluorescence profiles
for Cat L activity in the enriched cells were compared to the profiles for cells gated on
green positive staining for Mac1 or B220 molecules. Red fluorescence intensity due to
product formation for purified macrophages showed no significant difference from that for
gated Mac1+ cells from unfractionated splenocytes (Figure 7D; 48 MFI for purified cells
vs. 58 MFI for stained cells). Similarly, MFI values were comparable for purified B cells
and gated B220+ cells (Figure 7E; 56 MFI for purified cells vs. 58 MFI for stained cells).
Similar results were obtained for Cat B and S product profiles of isolated macrophages
versus Mac1+ cells, and purified B cells versus B220+ cells (data not shown). This
protocol measured cathepsin activities in cell subpopulations without the need for cell
purification.
Discussion
The assay I developed has the distinct advantage of assessing activity of Cat B, L
and S in live cells on a per cell basis using a low number of cells and could be easily
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Table 4
Cathepsin activities in spleen cells expressing Mac-1, B220, and Thy1.2 molecules.

Cathepsin

Mac 1 + cells

B220 + cells

Thy1.2 + cells

B

315 ± 76

204 ± 73

141 ± 55*

L

80 ± 15

67 ± 12

31 ± 5*

S

170 ± 31

142 ± 54

57 ± 14*

Cells were incubated with a cathepsin substrate followed by immunofluorescence staining
(see Figure 3 legend). Values are MFI ± SD for cathepsin activity in cells expressing the
indicated molecules from five separate experiments. *Thy 1.2+ cells vs. Mac1+ cells: P <
0.05. Reproduced with copyright permission.
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adapted for the clinical laboratory setting. Peptide substrates coupled to cresyl violet are
routinely utilized for confocal microscopy and have been infrequently applied to FCM.
Confocal microscopes and dual laser flow cytometers employ a helium neon laser to excite
cresyl violet at 543 nm. Single argon laser flow cytometers are very prevalent, and this
laser excites at 488 nm, which is below the peak excitation wavelength for the cresyl violet
leaving group (Boonacker, 2001). Despite this potential problem, cathepsin activity inside
cells was readily quantitated, and measurements depended on substrate concentration. Red
fluorescence values increased, whereas green fluorescence measurements were constant,
indicating higher product formation with increasing substrate concentrations. Key to
measuring substrate cleavage using an argon laser was appropriate compensation settings.
Furthermore, LPS stimulation of a macrophage cell line significantly increased red
fluorescence values for Cat B, L and S, suggesting that the substrates were not limiting.
The higher product measurements probably reflected increased proteolytic activities inside
stimulated macrophages. This was confirmed by performing cell lysate protease activity
assays for Cat B, L and S. Activity of all three cathepsins within cell lysates was
significantly increased in LPS-stimulated cells, which correlated with results obtained by
the FCM assay. Although there were slight differences in the fold increase values between
the two assays, this could possibly be attributed to product leakage from live cells, while
products accumulate in the cell lysate assay. Furthermore, higher values for Cat B and L
lysate assays also indicate reaction conditions probably drive activation of precursor Cat B
and L. Increased activity in the Cat S lysate assay, which is performed under neutral
conditions, was not observed, and mature Cat S retains 70% maximal activity. Although
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cleavage products could accumulate, precursor Cat S would not be activated at neutral pH.
Potential precursor activation in the cell lysate assays may account for the disparate rank
order of cathepsin activity between the assays. The possibility that the disparate rank order
is due to technological differences between the instruments is highly unlikely. When
AMC-coupled substrates, which were used for cell lysate assays, were adapted for live
cells, the rank order was identical. These results demonstrate the ability to use these
substrates with single argon laser flow cytometers to quantify intracellular cysteine
cathepsin activity.
Time courses indicated a 45-min incubation was sufficient to assess cysteine
cathepsin activity accurately. Incubations from 1 to 3 h showed no significant decrease in
measurements or quenching of the fluorescent product. These findings indicate that
steady-state conditions were stable during this time frame. Steady-state conditions
occurred earlier than that for cell lysate assays (Barrett, 1981; Kinschke, 1994). Time
kinetics for the whole cell assay is more complex than that for cell lysate assays. For the
former assay, substrates must be internalized by live cells and enter the proper organelles
where functional cysteine cathepsins reside. The fluorescent product can then diffuse from
cells (Boonacker, 2001). In contrast, cell lysate assays depend only on the reaction rate. In
addition, unlike substrates for cell lysate assays, cresyl violet is bi-substituted with
peptides. However, pseudo first-order rate kinetics can be achieved if less than 15% of the
substrate is cleaved (Boonacker, 2001). Immunofluorescence staining requires an
additional incubation of 1.5 h, and the time course determined that the extended incubation
time would have no effect on assessing cysteine cathepsin activity.
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Cysteine cathepsin activity was assessed in live or post-paraformaldehyde fixed
cells. There was no significant difference in Cat L and S measurements in live or postfixed cells. Although cresyl violet product diffuses from living cells (Boonacker, 2001),
paraformaldehyde fixation of cells apparently prevented product loss. Fixed cells were
stored for 14 days without a significant decrease in product measurements. However, Cat
B values were lower for live cells than post-fixed cells, which could not be attributed to
product leakage from live cells or the process of fixation. The reason for the lower
fluorescence in live cells remains unclear, but this result occurred only with the Cat B
substrate. Hence, comparisons of Cat B measurements with other cathepsins in post-fixed
cells need to consider this property of the Cat B substrate. Overall, these findings indicate
that cells can be fixed and stored before analysis without a loss of product.
Selectivity of substrate cleavage by a particular cathepsin was assessed by the use
of cell permeable general and selective inhibitors. However, the inhibitors were
problematic due to their toxicity to spleen cells, which is not an issue for cell lysate assays.
Therefore, 5-CFDA, AM was a marker for viable cells, which were gated by green
fluorescence to exclude dead cells. Pre-incubation of cells with cathepsin inhibitors
significantly decreased fluorescence intensity using the appropriate substrates, indicative
of lower proteolytic activity. Fluorescence intensities did not drop to baseline levels of
cells incubated in absence of substrate. Similar results were also obtained using AMCconjugated substrates with live cells, and measuring fluorescence with a
spectrofluorophotometer. The AMC-conjugated substrates are routinely used to measure
cathepsin activity in cell lysates (Barrett, 1981; Kinschke, 1994). Hence, the inability to
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reduce fluorescence intensities to baseline levels cannot be attributed to a problem with
cresyl violet-conjugated substrates or FCM measurements. Most likely, inhibitors did not
reach sufficient concentration levels within organelles of live cells to inactivate cysteine
cathepsins completely. Selectivity of the assays was further investigated by evaluating
non-selective cleavage. The Cat L selective inhibitor minimally decreased product
formation from Cat B substrate, which correlates with the extremely low affinity of the Cat
L selective inhibitor for Cat B (Barrett, 1981). The Cat L selective inhibitor impaired Cat
S substrate cleavage, but not to the extent seen with Cat L substrate. These findings agree
with the reported cleavage of the Cat S substrate by Cat L due to a low affinity interaction
(Brömme, 1989). Furthermore, the Cat S selective inhibitor had no effect on product
formation from Cat B or L substrates, which is in agreement with a previous report using
purified enzymes (Shaw, 1993). Taken altogether, non-specific cleavage was minimal, and
the selectivity of this assay parallels that reported for cell lysate assays (Barrett, 1981;
Brömme, 1989; Kinschke, 1994; Shaw, 1993). Additional experiments with cells from Cat
B, L or S genetically deficient mice would elucidate the exact degree of selective substrate
cleavage.
Peptide substrates coupled to rhodamine 110, an analogue of fluorescein, are nonfluorescent and have been utilized with live cells for FCM. Upon peptide cleavage, the
leaving group emits with a spectrum similar to fluorescein (Boonacker, 2001). These
substrates have disadvantages compared to cresyl violet-conjugated substrates. The
product is positively charged and accumulates within mitochondria (Boonacker, 2001).
Due to intracellular product accumulation, short incubation times and low substrate
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concentrations are typically employed for live cell measurements (Boonacker, 2003;
Ulbricht, 1995). In contrast, intracellular cresyl violet product localizes to the site of active
proteases (Boonacker, 2001; Boonacker 2003). Substrate cleavage specificity is influenced
by properties of fluorophores in synthetic substrates in addition to the peptide sequence.
Rhodamine 110-coupled peptide substrates for Cat B and L, and dipeptidyl peptidase IV
exhibit more promiscuous cleavage than substrates with the same amino acid sequence
conjugated to AMC, 4-methoxy-b-naphthylamide or cresyl violet (Boonacker, 2003;
Ulbricht, 1995).
Spectral overlap was a concern due to the emission spectrum of cresyl violet
perchlorate (Boonacker, 2001; Du, 1998). Fluorescein emits in the red channel to a very
low degree. To avoid false measurements, compensation settings were determined to
subtract signals in FL-1 channel. I also used a Beckman Coulter Cytomics FC 500, and
similar results were observed. The cell surface molecule detected by immunofluorescence
staining must be highly expressed, because spectral compensation decreases the sensitivity
of detectors to measure signals. Since many cell types, including tumor cells, highly
express at least one cell surface molecule, this disadvantage is minimal. I assessed the
activity of each cathepsin in spleen cells expressing Mac-1, B220, and Thy1.2 molecules.
The percentages of cells staining positively for these molecules were not influenced by the
substrates. Mac-1+ macrophages had the highest activity of all three cathepsins followed
by B220+ B cells, while Thy1.2+ T cells had the lowest cysteine cathepsin activity.
Without immunofluorescence staining, spleen cells showed unimodal fluorescent product
profiles, which masked the differences between T cells and B cells. Immunofluorescence
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staining clearly revealed that product measurements in T cells were half to one third of
those in macrophages and B cells. Cathepsin protein levels have not been measured in
these different cells types however, Cat B and S were highly active in Mac-1 and B220
expressing cells, which correlate with their function as antigen-presenting cells
(Berdowska, 2004; Chapman, 2006; Honey, 2003). Fluorescent product formation in
purified macrophages and B cells was equal to that obtained in unpurified cells gated for
Mac1+ or B220+ expression. The combination of this new cathepsin assay with
immunofluorescence staining allows one to assess cathepsin activity in multiple cell types
without the need for cell purification, which could be useful for diagnostic and prognostic
tests.
To determine the role of cysteine cathepsins in physiological and
pathophysiological processes, methods to measure proteolysis in individual viable cells are
needed. I developed a novel assay to measure Cat B, L and S activities in live cells on a
per cell basis utilizing FCM. This method is fairly rapid and can be performed with a low
number of cells. This technique was combined with immunofluorescence staining
allowing us to determine proteolytic activity in distinct cell types within a heterogeneous
cell population. Cells were fixed and stored before analysis without product loss.
Therefore, this assay could be used to evaluate clinical cell samples from peripheral blood
and various organs and easily adapted for high-throughput assessment. This method was
employed for my subsequent studies investigating regulation of cathepsin activities.

Note: This chapter, in part, was published in Cytometry Part A, 71A:114-123, 2007.
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Chapter 4: Toll-Like Receptor Regulation of Cysteine Cathepsins
Introduction
Previous studies investigating the effects of TLR-4 ligand, LPS, on cathepsins
are inconclusive due to conflicting data. Studies with dendritic cells indicate that LPS
alters the intracellular localization of active proteases within phagosomal and
endosomal compartments (Lautwein, 2002; Lennon-Dumenil, 2002). However, these
studies did not elucidate whether LPS affects overall cathepsin activity and expression.
Pro-inflammatory cytokines TNF-α, IL-1β and IL-6 are rapidly induced upon LPS and
PGN activation of multiple cell types, and these cytokines by themselves regulate
cathepsins in several cell types (Bjorkbacka, 2004; Hirschfeld, 2001; Jones, 2001;
Lautwein, 2002; Watari, 2000). Changes in cathepsin mRNA expression do not always
correlate with protein levels or increased activity (Keyszer, 1998), because cathepins
are regulated on several levels. These studies demonstrate differential regulation of Cat
B, L and S by cytokines and reveal differences among cell types. Few studies have
focused on TLR regulation of these proteases in macrophages, despite the fact they have
the highest expression of cathepsins in diseased tissues. Hence, the mechanisms by
which these proteases are upregulated during inflammatory diseases are poorly
understood.
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In the previous chapter, Cat B, L and S activities in live cells were increased in
response to LPS, however the impact of other TLR ligands on cysteine cathepsins have
not been investigated. In this chapter, I examined the effects of multiple TLR ligands
on cysteine cathepsins. This study focused on the regulation of cysteine Cat B, L and S
activities in macrophages during inflammatory responses to both MyD88-dependent
and -independent TLR ligands (Table 5), including TLR-2 ligand, PGN, TLR-4 ligand,
LPS, TLR-3 ligand Poly I:C and formalin-killed C. parvum. Changes in mRNA
expression of cathepsins and their endogenous inhibitors, cystatins, were measured at
early and late time points. Increased cathepsin activities occurred in the absence of
upregulated cathepsin gene expression, however cystatin C mRNA levels were
decreased.
To distinguish between a primary LPS signaling effect or a secondary cytokine
effect, a LPS non-responsive macrophage/microglial cell line was co-cultured with a
LPS responsive macrophage cell line. LPS-stimulated macrophages activated LPS nonresponsive bystander cells to upregulate cathepsin activity. In addition, cell-free culture
supernatants from macrophages stimulated with LPS for 6 h increased cathepsin
activities in LPS non-responsive macrophages, suggesting that cytokines produced early
in response to TLR ligands are involved. Furthermore, LPS non-responsive cells were
stimulated with culture supernatants pre-incubated with neutralizing anti-TNF-α or IL1β antibodies. Neutralization of TNF-α and IL-1β resulted in differential effects on
cysteine cathepsins. These results indicate that pro-inflammatory cytokines increased
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Table 5
TLR ligands, receptors and pathways investigated.
Ligand

Receptor

Response
MyD88
Dependent

MyD88
Independent

LPS

TLR-4

Classic in vitro
Inflammatory Model

+

+

PGN

TLR-2

Similar to LPS

+

-

PIC

TLR-3

Robust IFN-β Production

-

+

Whole Organism

+

+*

C.
TLR-2 & other
parvum
PRRs

+*; Involvement of other PRR.
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cathepsin activities in response to LPS and may play a role in downregulation of
cystatin C, an endogenous cysteine cathepsin inhibitor.
Results
TLR Ligands Increase Cathepsin Activities I investigated the effects of TLR
ligands on cysteine cathepsin activity in multiple macrophage cell lines. To measure
cathepsin activity inside live cells, cell permeable, selective peptide substrates
conjugated with AMC or MR were utilized.
Fluorescent AMC and MR products were measured by spectrofluorophotometry or flow
cytometry, respectively, based on their spectral properties (Creasy, 2007). Studies in
Chapter 3 employing these substrates revealed comparable results with the two assays
(Creasy, 2007). When P388D1 (Figure 8A) and Clone 63 (data not shown)
macrophages were stimulated with LPS for 24 h, activities of Cat B, L and S
significantly increased with Cat L showing the greatest augmentation in P388D1 cells.
A macrophage cell line from cannabinoid receptor subtype 2 (CB2) deficient mice had
low CD14 expression, which is a co-receptor critical for LPS signal transduction.
Therefore, I investigated their ability to respond to LPS. CB2-/- cells stimulated with
LPS significantly increased IL-1β and MCP-1 production, indicating they are LPS
responsive (data not shown). This cell line was utilized for studies in Chapter 5 and
details on its characterization are presented there. LPS stimulation of CB2-/macrophages for 24 h also significantly enhanced intracellular activities of Cat B, L and
S (Figure 8B-D). Dose-response and time course studies revealed that cathepsin
upregulation occurred by 18 h in cells incubated with 10 µg/ml LPS, with
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Cathepsin B

P388D1 Macrophages
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Cathepsin S

Cathepsin L
D

C

Figure 8. LPS stimulation increases cathepsin activities in live macrophages.
Macrophages were cultured with or without 1 µg/ml LPS for 24 h, and live cell
cathepsin activities were assessed by (A) spectrofluorophotometric or (B-D) flow
cytometric assays. (A) Cysteine cathepsin activities in P388D1 macrophages. Data are
representative of 3 or more separate experiments. LPS vs. medium: *P < 0.05. (B) Cat
B, (C) Cat L and (D) Cat S activities in CB2-/- macrophage cell line.
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average fold increase in MFI values for Cat B, L and S of 1.4, 1.8 and 1.4, respectively.
LPS at concentrations as low as 0.3µg/ml caused cathepsin activities to increase at 24 h
however, more significant increases were observed with doses of 1 µg/ml or higher
(Appendix, Figure S1). Cat B, L and S activities significantly increased at 24 h in CB2/-

, P388D1 and Clone 63 macrophages cultured with 1 µg/ml LPS. Activity remained

increased at 48 h, however longer time points were not analyzed due to cell loss that
occurs with extended incubation times. To insure increased fluorescence was due to
enhanced cathepsin activity within acidic intracellular organelles, the ImageStream®
Cell Analysis System was employed. This system combines FCM and fluorescent
microscopy allowing one to examine localization of fluorescent molecules, as well as
quantitative changes (Beuma, 2006). As shown in Figure 9, fluorescent product
generated by cleavage of Cat S MR-conjugated substrate in LPS-stimulated cells
remained localized to acidic vesicles and paralleled results obtained using confocal
microscopy (see Figure 3). Similar results were obtained for Cat B and L substrates,
and similarity bright detail scores supported co-localization (data not shown). Red
channel MFI of Cat B, L and S products in LPS-stimulated cells was compared to
medium control values and increased from 63,833 to 89,259, 61,384 to 104,810, and
105,907 to 117,262, respectively.
I extended the study to include other TLR ligands which signal through MyD88dependent or –independent pathways. Dose response studies were performed with PGN
and Poly I:C to determine an effective dose (Appendix, Figures S2 and S3). P388D1
macrophages stimulated with 4 µg/ml PGN, a TLR-2 ligand, for 24 h significantly
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DND-26

Cat S

Composite

Medium
Literature Cited

LPS

Figure 9. Increased activity of Cat S in LPS stimulated cells is localized within acidic
organelles.
Macrophages were cultured without or with LPS for 24 h, incubated with the MRconjugated Cat S substrate and LysoTracker DND-26. Analysis of live cells was
performed using the ImageStream® Cell Analysis System to detect fluorescent intensity
and localization of intracellular red fluorescent hydrolyzed product from Cat S substrate
and green LysoTracker DND-26.
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increased Cat L and S activities compared with medium controls (Figure 10A). While
Cat B showed a trend of increased activity this increase was not as significant as that
observed for Cat L and S. Similar results were obtained when P388D1 cells were
stimulated with 10 µg/ml Poly I:C, whereby only activities of Cat L and S were
significantly increased (Figure 10B). To examine the effects of signaling through
multiple PRR, cells were incubated with or without 10 µg/ml formalin-killed C. parvum
for 48 h. Cat B and S were significantly upregulated, whereas Cat L was not affected
(Figure 10C). To investigate the possible influence of phagocytosis of C. parvum on
cathepsin upregulation, cells were incubated with 1-mm diameter polystyrene beads.
The fold increase in MFI was 1.04 or less for the three cathepsins after phagocytosis of
the beads, thus Cat B, L and S were not increased due to phagocytosis of the beads.
TLR Ligands Induce Cathepsin Secretion
Cells regulate their intracellular levels of cysteine cathepsins by secreting pro
and active forms of the enzymes. During inflammation, cathepsins can degrade
extracellular matrix components, however whether cleavage occurs intracellularly or
extracellularly is not clear. I investigated whether LPS or PGN stimulation induced
secretion of active cathepsins. Cells were incubated with 1 µg/ml LPS, 4 µg/ml PGN or
medium containing 10 mM NH4Cl/mannose-6-phosphate, which was a positive control,
for 24 h. NH4Cl promotes secretion of endosomal and lysosomal proteins, and
mannose-6-phosphate prevents cellular re-uptake of secreted proteins by saturating
mannose-6-phosphate receptors. Cathepsin activity in cell-free culture supernatants was
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Figure 10. Differential impact of PGN, Poly I:C, and C. parvum stimulation on
macrophage cathepsin activities.
P388D1 macrophages were incubated without or with (A) 4 µg/ml PGN or (B) 10
µg/ml Poly I:C for 24 h. (C) CB2-/- macrophages were incubated with 10 µg/ml
formalin-killed C. parvum for 48 h. Live cell cathepsin activities were assessed by
spectrofluorophotometry (A&B) or flow cytometry (C). Data are the mean ± standard
deviation from 3 or more separate experiments. Fold increase was calculated by
dividing fluorescent values of stimulated cells by values of medium controls. PGN,
Poly I:C or C. parvum vs. medium: *P < 0.05; **P < 0.01.
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measured according to protocols for cell lysates as described in Chapter 2. Activity per
live cell of Cat B, L and S increased in culture supernatants from LPS-treated cells
(Figure 11). Similar results were obtained for culture supernatants from PGNstimulated cells (data not shown).
LPS Stimulation Decreases Cystatin C mRNA Expression
Possible mechanisms for changes in cathepsin activity were investigated
utilizing the LPS model system. To distinguish between direct effects of LPS signaling
and indirect effects, mRNA expression was examined at early and late time points.
RNA was isolated from cells stimulated with 1 µg/ml LPS for 6 h or 24 h, and
semiquantitative RT-PCR was performed. Cystatin A mRNA was not detected in LPSstimulated or medium control macrophages at either time point (data not shown). At
the 6-h time point, no changes in transcripts of Cat B, L, and S or the endogenous
inhibitors, cystatins B and C were observed (data not shown). As shown in Figure 12,
at 24 h there was a slight increase in mRNA expression of Cat B and L, but not S,
although the increase was not significant. Cystatin B mRNA expression was not altered
at 24 h, however cystatin C transcript decreased noticeably (Figure 12). Semiquantitative Real Time-PCR using SYBR GreenER™ Two-Step qRT-PCR confirmed
the results obtained for Cat B, L and cystatin C mRNA (Appendix, Figure S4).
Activation of LPS Non-responsive Bystander Cells
Pro-inflammatory cytokines, such as IL-1β and TNF-α, are readily produced by
macrophages activated by LPS and PGN (Jones, 2001; Hirschfeld, 2001), which may
mediate increased cathepsin activities. EOC 20 macrophage/microglial cell line is
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Figure 11. LPS induces cathepsin secretion.
CB2-/- macrophages were incubated in medium, 1 µg/ml LPS or 10 mM ammonium
chloride/mannose-6-phosphate (+ secretion control) for 24 h. Secreted enzymatic
activity per cell was measured in concentrated cell-free culture supernatants for (A) Cat
B, (B) Cat L and (C) Cat S. Values represent the mean ± standard error from 3 separate
experiments. *P < 0.05 compared with medium control.
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Medium Cys B
LPS Cys B
Medium Cys C
LPS Cys C
No RT Cys B & C
Medium β-actin
LPS β-actin

Medium β-actin
LPS β-actin

Medium Cat S
LPS Cat S
No RT Cat S

LPS Cat L
No RT Cat L
Medium β-actin
LPS β-actin

Medium Cat L

Medium Cat B
LPS Cat B
No RT Cat B

Cathepsins

Cystatins

Figure 12. Effects of LPS stimulation on mRNA expression of Cat B, L and S and
cystatins B and C.
P388D1 Macrophages were cultured with or without 1 µg/ml LPS for 24 h. Cells were
lysed and prepared for semiquantitative RT-PCR. Cat B, L, S, Cystatins (Cys) B and C
and β-actin cDNA were amplified at different cycle numbers to maintain linearity. Top
panels are representatives of 3 separate experiments. Bottom panels are mean ± SD of
relative expression compared with β-actin.
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derived from C3H/HeJ mice. These mice are LPS non-responsive due to a mutation
within the cytoplasmic domain of TLR-4 but are responsive to PGN and Poly I:C
(Takeuchi, 2000). As expected, EOC 20 cells cultured with LPS did not increase
cathepsin activities (Figure 13). I investigated the ability of EOC 20 cells to increase
cathepsin activities in response to PGN and Poly I:C. Similar to P388D1 cells (see
Figure 10), EOC 20 cells significantly upregulated Cat L and S activities in response to
PGN and Poly I:C (Figure 13). To investigate the role of cytokines, EOC 20 cells were
co-cultured with LPS responsive P388D1 cells at a 1:1 ratio and stimulated with LPS
for 24 h. Immunofluorescence staining was combined with the live cell cathepsin flow
cytometric assay. Staining for MHC class I Kk molecule, which is expressed by EOC
20 cells, was used to distinguish the two cell types and perform individual assessment
of cathepsin activities. Cells positive (EOC 20) and negative (P388D1) for H-2Kk were
gated and analyzed for cathepsin activities in the same manner as shown in Figure 7.
EOC 20 cells had increased activities of Cat B and L, but not S, when co-cultured with
P388D1 cells in the presence of LPS (Table 6). P388D1 cells from the co-cultures
displayed significant upregulation of Cat B and L relative to medium control cells with
a minimal fold increase of 1.7.
TNF-α and IL-1 Exert Differential Effects on Cathepsins
Increased Cat B and L activities in bystander EOC 20 cells suggest LPSstimulated P388D1 cells secreted cytokines leading to the increase. However, Cat S
activity did not increase in either cell line, which may be due to cell competition. To
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Figure 13. EOC 20 microglial cells are LPS non-responsive but upregulate cathepsin
activity in response to PGN and PIC.
EOC 20 cells were incubated without or with 1 µg/ml LPS, 4 µg/ml PGN or 10 µg/ml
Poly I:C for 24 h and assessed for live cell Cat B, L and S activities by flow cytometry
(top panels) or spectrofluorophotometry (bottom panels) . Data is representative of 3 or
more separate experiments. Fold increase was calculated as described in Figure 9. *P <
0.05 compared with medium control.
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Table 6
Bystander upregulation of cathepsin activities in LPS non-responsive cells.
P388D1 Med

P388D1 LPS

EOC Med

EOC LPS

Cat B

113 ± 17

195 ± 32

217 ± 20

296 ± 11*

Cat L

55 ± 10

121 ± 58

65 ± 3

155 ± 117

Cat S

128 ± 22

146 ± 24

138 ± 17

118 ± 6

EOC 20 cells were co-cultured with P388D1 macrophages in medium with or without 1
µg/ml LPS for 24 h. Cells were incubated with a cathepsin substrate followed by
immunofluorescence staining to detect MHC class I Kk on EOC 20 cells. Numbers
represent MFI values of Cat B, L and S activities in P388D1 and EOC 20 medium
(Med) control and LPS treated cultures. Data are the mean ± SD of 3 separate
experiments. Medium vs. LPS: *P < 0.05.
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further investigate cytokines’ role in enhanced cathepsin activity, P388D1 macrophages
were cultured in medium with or without LPS for 6 or 24 h. Then, EOC 20 cells were
incubated with P388D1 cell-free culture supernatants for 24 h and cathepsin activities
were assessed using live cell AMC assays. The 6-h culture supernatants significantly
increased activities of the three cathepsins in EOC 20 cells (Figure 14). In contrast, 24h culture supernatants had no effect on cathepsin activities in EOC 20 cells, indicating
that early cytokines enhanced cathepsin activity (Figure 14).
TNF-α is rapidly released from LPS-stimulated cells. Other pro-inflammatory
cytokines, such as IL-1β, are also secreted from TLR-activated macrophages. To
investigate the role of TNF-α and IL-1β, 6-h culture supernatants were incubated with
various concentrations of neutralizing anti-TNF-α or anti-IL-1β mAb, or correlating
concentrations of mouse IgG as a negative control. EOC 20 cells were then incubated
with antibody-treated culture supernatants for 24 h. Preliminary results revealed
P388D1 culture supernatants containing higher concentrations of neutralizing TNF-α
mAb inhibited upregulation of Cat B in EOC 20 cells when compared to IgG treated
controls (Figure 15). Cat L activity was only slightly reduced by neutralizing TNF-α
or IL-1β mAb (Figure 15 & 16). Activity of Cat S was also not significantly affected
when culture supernatants were treated with anti-TNF-α or anti-IL-1β mAb, suggesting
other cytokines may be responsible for it’s regulation (Figure 15 & 16). Neutralization
of IL-1β selectively inhibited upregulation Cat L activity but appeared to have no effect
on Cat B activity compared to IgG treated controls (Figure 16). These results
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Figure 14. P388D1 culture supernatants increase cathepsin activities in EOC 20 cells.
P388D1 macrophages were cultured in medium or 1 µg/ml LPS for 6 or 24 h. Cell-free
culture supernatants were harvested, concentrated, added to EOC 20 cell cultures and
incubated for another 24 h. EOC 20 cells were harvested and live cell AMC cathepsin
assays were performed. Fold increase was calculated by dividing the fluorescence
values for LPS-stimulated culture supernatants by the values for medium control culture
supernatants. LPS vs. medium: *P < 0.05; **P < 0.01.
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Figure 15. Neutralization of TNF-α in P388D1 culture supernatants reduces increased
activity of Cat B and L in EOC 20 cells.
P388D1 macrophages were cultured in medium or 1 µg/ml LPS for 6 h. Cell-free
culture supernatants were harvested, concentrated, and treated with the indicated
concentrations of anti-TNF-α monoclonal Ab or controls were treated with 3 µg/ml
IgG prior to addition to EOC 20 cell cultures EOC 20 cells were incubated for 24 h,
harvested and live cell AMC cathepsin assays were performed. Data are the mean ± the
standard deviation of three separate experiments. Medium IgG vs. LPS IgG: *P < 0.05.
LPS IgG vs. LPS anti-TNF-α: *P < 0.05.
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Figure 16. Neutralization of IL-1β reduces increased activity of Cat L but not Cat B
and S in EOC 20 cells.
P388D1 macrophages were cultured in medium or 1 µg/ml LPS for 6 h. Cell-free
culture supernatants were harvested, concentrated, and treated with the indicated
concentrations of anti-IL-1β monoclonal Ab or controls were treated with 20 µg/ml of
IgG prior to addition to EOC 20 cell cultures. EOC 20 cells were incubated for 24 h,
harvested and live cell AMC cathepsin assays were performed. Data are the mean ± the
standard deviation of two separate experiments. Medium IgG vs. LPS IgG: *P < 0.05.
LPS IgG vs. LPS anti-IL-1β: NS.
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suggest differential regulation of these cathespins by TNF-α and IL-1β and indicate the
involvement of other cytokines not investigated here.
Discussion
This study is the first one to examine the impact of other PRR ligands in
addition to LPS on cysteine cathepsins. I utilized two live cell enzymatic assays to
assess changes in cysteine cathepsin activities on a per cell basis in response to
inflammatory PRR stimuli in culture. LPS consistently increased Cat B, L and S
activities by 2- to 4-fold in several macrophage cell lines. In a similar manner, PGN, a
TLR-2 ligand, and Poly I:C, a TLR-3 ligand, also enhanced proteolytic activity of Cat L
and S. Lower levels of enhanced Cat B activity in response to PGN and Poly I:C
suggests that increased Cat B activity is dependent on activation of both MyD88dependent and -independent pathways, which occurs with only LPS. All together this
study demonstrates cathepsins can be altered in response to both MyD88-dependent and
–independent TLR ligands. In contrast, macrophages incubated with formalin-killed C.
parvum increased activity of Cat B and S, but not L. C. parvum signals through TLR-2
as well as other PRR. Perhaps, C. parvum activated a pathway that negated a positive
signal for upregulating Cat L. Phagocytosis alone could not explain the disparate
results, because cells cultured with polystyrene beads had no change in cathepsin
activity. This supports the idea that PRR signaling activated by C. parvum causes
alterations in cathepsin activity.
Previous studies have shown a lack of correlation between altered cathepsin
activity and mRNA expression (Keyszer, 1998). I observed a significant increase in
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cathepsin activity in LPS stimulated cells, which occurred in the absence of increased
cathepsin mRNA expression. Cystatins, endogenous inhibitors of cysteine cathepsins,
are often inversely affected during inflammatory diseases. These data support this
trend, showing decreased levels of cystatin C may contribute to the increased activity of
cathepsins during the inflammatory response. Interestingly, the intracellular inhibitor
cystatin B, was not altered during the LPS response, suggesting its role in regulation of
these proteases during inflammation may be minute. Furthermore, changes in cystatin
C mRNA expression occurred at later time points suggesting an indirect role for TLR
signaling in regulating these proteases. Signaling through TLR induces production and
secretion of pro-inflammatory cytokines, which have been shown to regulate cathepsin
expression and activity (Watari, 2000; Fiebiger, 2001; Kitamura, 2005). The time at
which changes in expression occurred in this study indicate pro-inflammatory cytokines
produced in response to LPS lead to increased cathepsin activities.
TNF-α, IL-1β and IL-6 secretion rapidly occur in LPS-stimulated macrophages
although increases in TNF-α typically occur quicker than IL-1β and IL-6. These proinflammatory cytokines have been reported to upregulate Cat B and S, although the
results depend on the cell type (Jones, 2001; Fiebiger, 2001). P388D1 macrophages
were LPS responsive, whereas EOC 20 cells were LPS non-responsive. In 24-h cocultures, EOC 20 cells increase Cat B and L activities, indicating a secondary
mechanism was involved in cathepsin upregulation. When this study was extended to
examine the effects of culture supernatants from LPS-stimulated P388D1 cells on
cathepsin activity of EOC 20 cells, the early cytokine response played a significant role
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in the regulation of cathepsins. In contrast to co-culture experiments, upregulation of
Cat S activity was observed in the culture supernatant studies. An unknown
mechanism, which controls Cat S, may have occurred in co-cultures or co-culture
conditions were not optimal for Cat S upregulation. EOC 20 cells are capable of
binding LPS even though their signaling cascade is defective. Therefore, availability of
LPS to P388D1 cells may have been limited in co-cultures. Neutralization of TNF-α
and IL-1β had differential effects on Cat B, L and S. Cat L appears to be regulated by
both TNF-α and IL-1β, whereas Cat B activity was decreased only when TNF-α was
neutralized. Cat S was not affected by neutralization of either of these cytokines
suggesting another cytokine(s), possibly IL-6, contributes to Cat S regulation. Activity
levels of Cat L and S were not reduced to medium control values when a single
cytokine was neutralized. This suggest TNF-α and IL-1β together or in conjunction
with other cytokines control these proteases, possibly by decreasing the expression of
cystatin C.
The extracellular microenvironment of inflamed tissues becomes acidic enough
to allow cathepsins to retain activity (Gatenby, 2006). For this reason, secretion of
active cathepsins from TLR-stimulated macrophages was also investigated. Both LPS
and PGN activation of macrophages increased active cathepsins in culture supernatants
by approximately 5-fold compared to cells incubated in medium alone, suggesting
induced secretion of active proteases. Cell viability in the various cultures was
comparable, and enzymatic activity was calculated per live cell. Thus, the likelihood
that enhanced cathepsin activity in LPS and PGN culture supernatants was due to
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release of proteases from dead cells is remote. However, the level of protease activity
in culture supernatants was minimal when compared intracellular activity, and,
therefore, the biological relevance of this secretion is questionable.
In conjunction, these studies show cathepsin activities were altered in response
to both MyD88-dependent and –independent TLR ligands. TLR ligands are currently
being investigated as possible vaccine adjuvants as well as for other immunotherapy
applications. Understanding the regulation of these proteases by these ligands is
important when considering their use for immunotherapy. Furthermore, macrophages
activated by TLR ligands caused cathepsin activities to increase in non-responsive
bystander cells increasing their role in pathogenesis. Culture supernatants from 6-h
LPS-stimulated macrophages increased cathepsin activity in LPS non-responsive
macrophages, which was diminished by neutralization of TNF-α and IL-1β. LPSstimulated macrophages had decreased levels of cystatin C mRNA, which may have
contributed to increased proteolytic activity. However, cystatin C also regulates Cat S,
which was not affected by neutralization of TNF-α or IL-1β suggesting the involvement
of other mechanisms for Cat S. Altogether these studies suggest TLR antagonists and
other therapeutic agents targeting pro-inflammatory cytokines involved in cathepsin
regulation may be useful in controlling cathepsins during chronic inflammatory
diseases.
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Chapter 5: Cannabinoid Inhibition of Cysteine Cathepsin
Upregulation During an Inflammatory Response
Introduction
Marijuana has long been used for medicinal purposes, dating back to the
Neolithic period, around 4000 BC (Benamar, 2006). THC along with endogenous
cannabinoids, and synthetic cannabinoids derivatives are currently being investigated as
possible therapeutic candidates. Cannabinoids, including THC, alter inflammatory
responses by immune cells, in particular macrophages. Stimulation of cells with LPS is
frequently used as a classical model for inflammation leading to NFκB activation and
production of pro-inflammatory cytokines. In the previous chapter cysteine cathepsin
activities were increased in macrophages stimulated with LPS and cytokines contributed
to this increase. THC attenuates iNOS gene expression, NFκB activation, and cytokine
production during macrophage response to LPS (Cabral, 2005; Jeon, 1996).
Cannabinoids also interfere with processing of intact antigens by macrophages and
increase cathepsin D activity. Other proteases, such as MMP, are also modulated by
cannabinoids (Blazquez, 2003; 2008). MMP and cathepsins play a key role
angiogenesis and tissue destruction and are similarly altered during inflammatory
disease. These findings support the possibility that cannabinoids may affect cysteine
cathepsins during inflammation.
This study investigated the ability of cannabinoids, THC and CP55940, to
modulate cathepsins during an inflammatory response. To investigate this possibility,
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P388D1 macrophages were pre-treated with THC or CP55940 prior to LPS stimulation
and cathepsin activity was assessed using live cell enzymatic assays. THC and
CP55940 reduced the levels of cathepsin upregulation in LPS-stimulated cells. Multiple
studies investigating immune modulation by cannabinoids using LPS as a model for
inflammation have been reported (Cabral, 2005; Klein, 2006; Jeon, 1996). However, the
mechanisms by which cannabinoids mediate these effects are not well elucidated. LPS
activation of macrophages requires cell surface expression of TLR-4 and it’s coreceptor CD14. Because cannabinoids interfere with multiple responses occurring in
LPS-stimulated macrophages, the possibility that cannabinoids downregulate the
surface expression of these molecules was investigated. Some studies have suggested
the immunosuppressive effects of cannabinoids can be attributed to their ability to
induce immune cells to undergo apoptosis (Guzman, 2005; Lombard, 2007). Therefore,
the possibility reduced cathepsin activities were related to cell death was also examined.
Immune modulation by cannabinoids, including THC may be mediated through
cannabinoid receptors CB1 and CB2. Immune cells primarily express CB2, however the
expression of cannabinoid receptors can be altered upon cellular activation (Carlisle,
2002). In this study the mRNA expression of cannabinoid receptors CB1 and CB2 was
examined in resting and LPS activated macrophages. P388D1 macrophages expressed
only the CB2 receptor, suggesting the modulation of cathepsins by cannabinoids was
CB2 receptor mediated. To further investigate the involvement of the CB2 receptor a
macrophage cell line derived from CB2-/- mice was utilized. Cannabinoid modulation of
cathepsins was absent in macrophages lacking CB2 expression. These results indicate
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cannabinoids via the CB2 receptor interfere with increased cysteine cathepsin activities
during an inflammatory response.
Results
Cannabinoid Receptor Expression in P388D1 Macrophages
Expression of cannabinoid CB1 and CB2 receptors in resting and LPSstimulated P388D1 cells was assessed. P388D1 cells were incubated in medium without
or with 1 µg/ml LPS for 6 or 24 h, and RNA was prepared. CB1 mRNA was not
detected in resting or LPS-stimulated P388D1 cells at either time point (Figure 17)
whereas CB1 transcripts were readily found in bone marrow macrophages from 129
mouse strain. In contrast, P388D1 cells expressed CB2 mRNA in both resting and
activated states. However, the expression level of CB2 mRNA did not significantly
alter upon LPS stimulation at either 6 or 24 h.
THC Inhibits LPS-Induced Cathepsin Upregulation
As shown in Chapter 4, macrophages upregulated cathepsin activities during the
inflammatory response to LPS. After confirming P388D1 cells expressed the CB2
receptor, the ability of cannabinoids to modulate cysteine cathepsins in LPS-stimulated
macrophages was investigated. P388D1 macrophages were pre-treated with vehicle or
various concentrations of THC, followed by LPS stimulation for 48 h. Cells were
harvested, and live cell cathepsin assays were performed using AMC-conjugated
substrates as described in Chapter 2. As shown in Figure 18, LPS activation caused
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Figure 17. Cannabinoid receptor expression in P388D1 macrophages.
P388D1 macrophages were cultured without or with LPS for 6 or 24 h. RNA was
prepared for semi-quantitative RT-PCR. CB1, CB2 and β-actin cDNA were amplified
at different cycle numbers to maintain linearity. Top panels are representatives of 3
separate experiments. Bottom panels are the mean relative CB2 expression compared
with β-actin ± SD at the indicated time points. 129 bone marrow (BM) macrophages
were used as a positive control for CB1 mRNA.
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Figure 18. THC inhibits upregulation of cysteine cathepsins in LPS-stimulated
macrophages.
P388D1 macrophage cell line was pre-incubated with various THC concentrations or
0.1% ethanol (vehicle) for 4 h at 37°C then incubated with 1 µg/ml LPS or medium for
48 h. Cathepsin activity in live cells was assessed using AMC-conjugated substrates as
described in Chapter 2. Values represent mean ± SE from 3 or more separate
experiments. Medium vehicle or LPS vehicle controls: *P < 0.05. Medium vehicle vs.
medium THC: NS. LPS vehicle vs. LPS THC: *P < 0.05.
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increased cathepsin activities in vehicle-exposed cells, in agreement with the results in
the preceding chapter (see Figure 8). THC did not significantly change cathepsin
activities in medium control cells (Figure 18). At 1 nM, THC significantly inhibited
cathepsin enhancement in LPS-stimulated P388D1 macrophage cell line. Activities of
Cat B, L and S were reduced to medium control levels. In general, higher THC
concentrations were less inhibitory. Decreased cathepsin activities in THC-exposed
cells were not due to loss of cell viability as assessed by trypan blue exclusion. THC is a
partial cannabinoid receptor agonist. The influence of CP55940, a full agonist, on
cathepsin activities was also examined. Unlike THC, CP55940 tended to increase
cathepsin activities in medium control cells in 24-h cultures (Figure 19). Although
CP55940 was less effective than THC at suppressing cathepsin upregulation in LPSstimulated cells, decreased cathepsin activity was more dose-dependent and could not
be attributed to cell death.
Characterization of CB2-/- Bone Marrow Macrophage Cell Line
Because P388D1 cells only expressed the CB2 receptor, the role of this receptor
was examined. To investigate the involvement of the CB2 receptor in modulating
cathepsins during an inflammatory response, a bone marrow (BM) macrophage cell line
from mice deficient for CB2 receptor was generated in collaboration with Dr. Howard
Young at the National Institutes of Health, as described in Chapter 2. The cells
expressed cell surface molecules typical of macrophages and lacked those expressed by
DC (Table 7). Co-stimulatory molecules expressed by CB2-/- macrophage cell line
were fully functional, because co-stimulatory activity was inhibited by antibodies
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Figure 19. CP55940 reduces cathepsin upregulation in LPS stimulated macrophages.
P388D1 macrophage cell line was pre-incubated with vehicle or the indicated
concentrations of CP55940 for 4 h at 37°C then culture without or with 1 µg/ml LPS for
24 h. Cathepsin activity in live cells was assessed (see Figure 18 legend). Values are
mean ± SE from 3 or more separate experiments. Medium vehicle vs. LPS vehicle: *P <
0.05. Medium vehicle vs. medium CP55940: NS. LPS vehicle vs. LPS CP55940: NS.
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Table 7
CB2-/- macrophage cell surface molecular expression.
Molecule

Expression Level

Mac-1

+++

ICAM-1

+++

FcγR

+

CD14

Low

B7-1

Low

B7-2

+

CD48

++

DEC-205

Negative

CD11c

Negative

I-Ab

Negative

Immunofluorescence staining for cell surface molecules on CB2-/- macrophages was
analyzed by flow cytometry. +++ Very High; ++ High; + Med-High.
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specific for B7-1, B7-2, CD48 and ICAM-1 (Personal Communication, K. McCoy).
Due to their low CD14 expression, a co-receptor required for LPS responses, their
ability to respond to LPS was investigated. CB2-/- cells stimulated with LPS increased
IL-1β and MCP-1 production, indicating they are LPS responsive (Personal
Communication, K. McCoy). Fcγ receptors of CB2-/- macrophages mediated
phagocytosis of rat IgG-coupled carboxylated beads normally (Personal
Communication, K. McCoy). Lack of CB2 mRNA expression was confirmed (Figure
20), and CB1 mRNA in resting and LPS-stimulated CB2-/- cells was assessed after 24 h.
Similar to P388D1 macrophages, CB1 mRNA expression was not detected in resting or
LPS-activated CB2-/- macrophages (Figure 20). Therefore, the CB2-/- macrophage cell
line expressed functional cell surface molecules required for phagocytosis, costimulation of helper T cells and LPS response, and lacked expression of cannabinoid
CB1 and CB2 receptors.
THC Inhibition Requires CB2 Receptor Expression
The ability of THC to suppress cathepsin activities in LPS-stimulated CB2-/macrophages was investigated. These cells increased cathepsin activities in response to
LPS (see Figure 8). As above, CB2-/- cells were pre-incubated with THC or vehicle
before LPS stimulation for 24 h, and live cell cathepsin assays were performed. THC
did not inhibit upregulation of cathepsin activities in CB2-/- cells during the LPS
response (Figure 21). The lack of CB1 mRNA expression in both macrophage cell lines
combined with the inability of THC to modulate cathepsin upregulation in CB2-/macrophages suggest a direct role for the CB2 receptor.
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Figure 20. Lack of cannabinoid receptor expression in CB2-/- macrophages.
CB2-/- macrophages were cultured without or with 1µg/ml LPS for 24 h. RNA was
prepared for semi-quantitative RT-PCR. CB2 and β-actin cDNA were amplified at
different cycle numbers to retain linearity. Amplification of CB1 cDNA proceeded for
44 cycles. Data are representative of 3 separate experiments.
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Figure 21. THC-mediated inhibition of cathepsin upregulation requires CB2 receptor
expression.
CB2-/- macrophage cell line was pre-incubated with vehicle or various THC
concentrations for 4 h at 37°C and then cultured without or with 1 µg/ml LPS. After
another 24 h, cathepsin activity in live cells was assessed (see Figure 18 legend). Values
represent mean ± SE from 3 or more separate experiments. Medium vehicle vs. LPS
vehicle: *P < 0.05. Medium vehicle vs. medium THC: NS. LPS vehicle vs. LPS THC:
NS.
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THC Does Not Cause Apoptosis in P388D1 Cells
Some studies have reported that cannabinoids induce apoptosis in immune cells.
The possibility THC causes macrophages to undergo apoptosis, thereby reducing their
response to LPS was investigated. P388D1 cells were treated with various THC
concentrations, vehicle or sodium arsenite as a positive control for 18 h. Cells were
harvested, stained with FITC Annexin-V and analyzed by flow cytometry. As shown in
Figure 22 THC did not induce apoptosis in P388D1 cells, even at a concentration 1000fold higher than what significantly inhibited cathepsin upregulation in LPS-stimulated
macrophages. Furthermore, viability assessments after 24 and 48 h in culture using
trypan blue exclusion were performed for all above experiments, and average cell
viability was greater than 90%, ruling out necrotic cell death as well.
THC Does Not Effect TLR-4 and CD14 Cell Surface Expression
LPS signaling requires TLR-4, MD2 and CD14 expression. The effect of THC
on cell surface expression of these receptors and co-receptors was assessed. P388D1
cells were incubated with THC or vehicle for 4 h, and immunofluorescence staining was
performed. The monoclonal antibody employed is specific for the functional TLR4/MD2 complex. Cell surface expression of these molecules did not differ between
vehicle- and THC-treated cells (Figure 22).
Discussion
This study is the first one to demonstrate that a cannabinoid influences cysteine
cathepsins during an inflammatory response. LPS is the most extensively studied TLR

110

FITC-Annexin V
10 µM
THC

2 µM
arsenite

Vehicle

Figure 22. THC does not induce apoptosis in P388D1 macrophages.
P388D1 cells were incubated with 10 µM THC, 2 µM sodium arsenite as a positive
control, or 0.1% ethanol for 18 h. Cells were incubated with FITC-Annexin V and
analyzed by flow cytometry.
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Figure 23. THC does not alter TLR-4/MD2 or CD14 surface expression.
P388D1 macrophages were incubated with vehicle or the indicated doses of THC for 4
h at 37°C. Cells were harvested and stained for TLR-4/MD2 or CD14 and analyzed by
FCM.
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ligand and is a classic model for inflammation. LPS significantly increased Cat B, L and S
activities in P388D1 macrophage cell line. THC concentrations in the nM range inhibited
cathepsin enhancement in LPS-stimulated P388D1 cells, but did not affect cathepsin
activities in medium control cells. CP55940 also reduced the level of LPS- increased
cathepsin activities, however the degree of suppression was less than that observed with
THC, which was unexpected. THC is a partial agonist, whereas CP55940 is a full agonist.
The results between may be related to the doses utilized. THC was most effective between
1 nM and 10 nM, while 100 nM was less inhibitory, suggestive of a biphasic response. A
number of studies indicate higher concentrations of CP55940 are required to obtain
inhibitory effects on macrophage function (Klein, 2006; Raborn, 2007). Perhaps, higher
CP55940 concentrations than those examined may be most effective at inhibiting
upregulation of cathepsin activities. Biphasic responses of immune cells are often
observed with cannabinoids, although the mechanisms involved are not fully understood.
Overall this study shows THC effectively inhibited the enhancement of cathepsin activities
during inflammation.
Cannabinoids have been reported to induce apoptosis especially in cell lines. Live
cell enzymatic assays were utilized to investigate the ability of cannabinoids to interfere
with increased cathepsin activities during the inflammatory response. These assays
exclude that decreased enzymatic activity was due to cell death. Furthermore, 10 mM
THC did not induce apoptosis in P388D1 cells while the cells were sensitive to arsenitemediated apoptosis. Therefore, apoptosis cannot account for cannabinoid downregulation
of cathepsin activities.
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Cannabinoids, including THC, may mediate immune modulation through
cannabinoid CB1 and CB2 receptors (Schatz, 1997). While immune cells primarily express
the CB2 receptor, various stimuli can alter the expression of these receptors. Stimulation
of HL-60 cells with phorbol ester increases CB2 mRNA expression. RAW 264.7 cells do
not express CB1 receptor in their resting state, which is consistent with multiple immune
cell types. However, in response to LPS, CB1 mRNA is induced within hours in this
macrophage cell line (Friedman, 1995). Furthermore, cannabinoid receptor expression on
macrophages is downregulated in response to IFN-γ or LPS (Caslisle, 2002). The mRNA
expression of CB1 and CB2 was assessed in resting and LPS-stimulated P388D1 cells at 6and 24-h time points. LPS-stimulation did not cause any significant difference in CB2
mRNA expression. Furthermore, there was no detectable CB1 mRNA in resting or LPSstimulated P388D1 cells indicating that the inhibitory effect observed with THC was not
mediated through the CB1 receptor. Utilizing a macrophage cell line deficient for CB2
receptor, the role of this receptor was investigated. Previous studies characterizing the
CB2-/- mice demonstrate a lack of cannabinoid-mediated immune modulatory effects in
these mice (Buckley, 2000). A macrophage cell line was generated from these mice, and
characterization of this cell line revealed it expressed surface molecules characteristic of
macrophages and lacked molecules expressed on DC. These cells were also capable of
multiple macrophage functions, including phagocytosis and LPS response to secrete
cytokines. CB2-/- macrophages not only lacked mRNA expression of CB2, but also CB1,
even after stimulation with LPS. Analogous to P388D1 cells, LPS augmented cathepsin
activities in CB2-/- cells. However, the inhibitory effect of THC was not observed in LPS114

stimulated CB2-/- macrophages. This finding indicates the CB2 receptor is required for
modulation of cathepins by THC during an inflammatory response.
Cannabinoids interfere with multiple macrophage functions. For example, alveolar
macrophages isolated from chronic marijuana users are compromised in their ability to
produce pro-inflammatory cytokines, such as TNF-α and IL-6, in response to LPS
stimulation (Baldwin, 1997). In addition, macrophage cell line RAW 264.7 treated with
THC has attenuation of LPS-stimulated iNOS gene expression, which is mediated by
inhibition of NF-κB activation (Jeon, 1996). No studies to date have investigated the
possibility that THC alters cell surface expression of receptors and co-receptors required
for LPS responses. In my study, THC did not change the expression of active TLR-4/MD2
complex or CD14, a co-receptor for LPS. However this does not rule out the possibility
that THC affects events downstream in the TLR-4 signaling cascade, thereby leading to the
decreased activities observed in THC-treated cells stimulated with LPS. TLR-4 signaling
leads to the rapid activation of NF-κB. This transcription factor is a key regulator of
cytokine production and, therefore, cannabinoid modulation may be due to a decrease in
pro-inflammatory cytokines, which control these proteases.
These results indicate THC via the CB2 receptor interfered with increased cysteine
cathepsin activities during an inflammatory response. The inhibitory effect exerted by
THC could not be attributed to apoptosis or alteration of cell surface receptors required for
LPS response. Similar to MMP, cysteine cathepsins contribute to pathological tissue
destruction and tumor angiogenesis. These findings support the possibility of CB2
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receptor-selective agonists as therapeutic agents for chronic inflammatory diseases to
prevent cathepsin involvement in pathological tissue destruction.
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CHAPTER 6: DISCUSSION
TLR Regulation of Cysteine Cathepsins
Cysteine cathepsins participate in joint destruction in RA, tumor angiogenesis,
formation and instability of atherosclerotic plaques, and pathological tissue destruction in
multiple other chronic inflammatory diseases (Berdowska, 2004). Regulation of these
proteases during inflammation is not well elucidated. Although cell activation by TLR
ligands contributes to the pathology of chronic inflammatory diseases, the impact of TLR
ligands other than LPS on cathepsins has not been investigated. I hypothesized that
stimulation through TLR’s would augment cysteine cathepsin activities, which would be
an integral part of an inflammatory response. In my studies, LPS, PGN and Poly I:C
increased cathepsin activities in macrophages. This increase was, in part, mediated by IL1β and TNF-α, pro-inflammatory cytokines. Decreased cystatin C gene expression
accompanied increased cathepsin activities in LPS-stimulated macrophages. Hence,
diminished expression of this endogenous protease inhibitor may contribute to the
enhanced cathepsin enzymatic activity.
LPS signals through TLR-4 and activates both MyD88-dependent and –
independent signaling cascades (Takeda, 2004). This stimulus increased activity of Cat B,
L and S in various macrophage cell lines. MyD88-dependent and –independent ligands
regulated the three cathepsins differently from LPS. PGN stimulus through TLR-2 is
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strictly MyD88-dependent, whereas the Poly I:C signal via TLR-3 is independent of
MyD88 (Trinchieri, 2007). Both ligands significantly increased Cat L and S activities,
however enhancement of Cat B activity was minimal. Hence, stimulated Cat L and S
activities occurred by either pathway. LPS and PGN stimulation enhanced Cat B activity,
however LPS was much more effective. These findings imply that more significant
increases in Cat B activity may require activation of both MyD88-dependent and independent pathways. Furthermore, Cat B upregulation does not occur through activation
of only the MyD88-independent pathway.
Multiple cytokines induced by TLR activation regulate cysteine cathepsins,
however, the outcome depends on the cell type and these findings are described in detail in
Chapter 1 (Chae, 2007; Honey, 2001;2003; Lemaire, 1997). Very few studies have
investigated cytokine regulation of these proteases in macrophages. There are significant
differences in macrophage cytokine production in response to various TLR ligands. LPS
rapidly induces gene expression of IL-1β, TNF-α, IL-6, IL-12 and IFN-γ in macrophages
(Hirschfeld, 2001; Bjorkbacka, 2004; Jones, 2001; Kawai, 2001). All of these cytokines
affect can cathepsin activity or expression. Secretion of IL-1β, TNF-α, and IL-6 also
occurs in response to TLR-2 ligands by macrophages, however cytokine levels are lower,
particularly IL-1β and IL-6, compared with those after LPS stimulation. (Hirschfeld,
2001; Jones, 2001; 2005). The duration of increased cytokine gene expression is also
shorter when signaling through TLR-2, and induction of IL-12 and IFN-γ are not usually
observed (Hirschfeld, 2001). Similar to TLR-2, TLR-3 induces low-level production of IL1β, TNF-α, and IL-6 but causes a robust IFN response. My studies showed antibody
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neutralization of TNF-α in culture supernatants from LPS-stimulated P388D1 cells
completely prevented upregulation of Cat B activity in LPS-non-responsive EOC 20 cells
demonstrating an obligatory dependency on TNF-α. Therefore, reduced TNF-α
production in response to PGN and Poly I:C may not reach a threshold sufficient to induce
Cat B upregulation and may be responsible for the lower levels of increased Cat B activity
in response to these TLR ligands. Antibody neutralization of TNF-α or IL-1β in P388D1
culture supernatants significantly reduced the increased Cat L activity in EOC 20 cells, but
neither antibody alone decreased Cat L proteolysis to medium control level. I predict
neutralization of both cytokines simultaneously would have a greater effect on Cat L
activity. Results with Cat S were distinct. In contrast to Cat B and L, Cat S activity was
not affected by antibody neutralization of TNF-α or IL-1β. Therefore, Cat S upregulation
was not dependent upon on these two cytokines. Other cytokines, such as IL-6 and IFN-γ,
IFN-β which were not investigated here, could contribute to Cat S upregulation. While the
exact role of individual cytokines was not completely delineated, TNF-α and IL-1β are
clearly important for increased Cat B and L activities in macrophages during an
inflammatory response. Furthermore, there is differential regulation of Cat B, L and S by
MyD88-dependent and –independent TLR ligands.
I originally predicted cathepsin upregulation would be MyD88-dependent because
of vigorous cytokine production. Studies indicate pro-inflammatory cytokines regulate
cathepsins, and the same cytokines are produced in a MyD88-dependent manor upon TLR
stimulation (Bjorkbacka, 2004). Poly I:C, which tranduces a MyD88-independent signal,
induces a low level of pro-inflammatory cytokine production in comparison to LPS. Based
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on my premise, Poly I:C would have little effect on these proteases. Unexpectedly, Cat L
and S activities in P388D1 cells were highest in response to Poly I:C with average fold
increases of 4.4 and 3.6, respectively. Perhaps, Poly I:C stimulation induces a different
mechanism for enhanced cathepsin activity from that after LPS activation. Unlike LPS
and PGN, Poly I:C causes a robust IFN-β response (O’Neil, 2002; 2006; Trinchieri, 2007).
Interferons may play an important role in the regulation of these proteases and possibly
compensate for the low levels of TNF-α and IL-1β produced in response to Poly I:C.
Recently, it was demonstrated IFN production by macrophages in response to Poly I:C
leads to the induction of other IRF-dependent gene products, such as IL-27 (Pirhonen,
2007). IL-27 increases cell surface expression of MHC class I and II molecules, and might
contribute to the regulation of cathepsins (Feng, 2007). IFN-γ increases Cat L expression in
macrophages, however an IRSE element has not been identified in the Cat L promoter
(Lah, 1995). IFN-γ also increases Cat S expression in multiple cells types (Zheng, 2005;
Strom, 2002). IFN production in response to Poly I:C leads to the activation of IRF-1,
which regulates Cat S expression in lung epithelial cells (Pirhonen, 2007; Storm, 2002). In
my studies, mRNA expression of Cat L and S was not altered in response to LPS, however
changes in cathepsin gene expression in cells stimulated with Poly I:C were not
investigated. In contrast to Cat L, IFN-γ decreases Cat B mRNA expression in
macrophages, although activity was not measured in this study (Liuzzo, 1999). This result
raises the possibility IFN-γ counteracts the low level production of TNF-α in Poly I:C
stimulated cells, thereby preventing changes in Cat B activity. Future studies would
investigate the effect neutralizing Ab to IFN-α, IFN-β, IFN-γ and IL-27 exert on cathepsin
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activities in macrophages stimulated with Poly I:C. These studies indicate the disparity in
cytokine production that occurs in response to the various TLR ligands regulate cysteine
cathepsins in a differential manor.
I hypothesized both direct and indirect mechanisms of TLR signaling would
regulate cysteine cathepsins. Transcription factors, such as NFκB, AP-1, SP-1 and IRF are
activated by TLR signaling cascades, and these transcription factors have been shown to
regulate cysteine cathepsins. The Cat B promoter region contains several SP-1 sites and a
NFκB binding site (Bien, 2003; Quian, 1991). IFN-γ alters mRNA expression of Cat B in
microglia, primary alveolar macrophages and macrophage cell lines, however an ISRE has
not been identified in the Cat B promoter (Liuzzo, 1999). The promoter region for Cat L
contains two AP-2, a SP-1 cluster and a cAMP response element (Ishidoh, 1989). The 5´
untranslated region of the human Cat S gene contains two SP-1 sites, an ISRE site and at
least 18 AP1 sites (Shi, 1994). Therefore, I expected to observe some direct effects
mediated through TLR signaling cascades. However, the results did not indicate direct
effects. The earliest time point at which increases in cathepsin activities were detected was
18 h, supporting the involvement of a secondary mechanism. In addition, the levels of
increased activity in EOC 20 cells treated with P388D1 culture supernatants were almost
identical to the levels of TLR ligand-stimulated cells. Furthermore, neutralization of TNFα completely inhibited the upregulation of Cat B. The gene expression of cathepsins and
their endogenous inhibitors, cystatins, was not altered in cells stimulated with LPS for 6 h,
further supporting the lack of direct TLR signaling effects. These results indicate the
effects of TLR signaling on cysteine cathepsins are primarily indirect and mediated by
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cytokines.
The increase in cathepsin activities in LPS-stimulated cells may be partially
mediated by decreases in cystatin C mRNA expression. LPS stimulation of cells decreased
cystatin C expression, but did not significantly change cathepsin mRNA expression.
Hence, cytokines did not affect cathepsin gene expression. While neutralization of TNF-α
and IL-1β reduced upregulation of Cat B and L activities, there was no effect on Cat S.
Yet, cystatin C inhibits all three cathepsins. Thus, the lack of cytokine neutralization
affecting Cat S suggests that these cytokines may not regulate cystatin C. This also raises
the possibility that mechanisms other than decreased cystatin C lead to increases in
cathepsin activity. Although cystatin C is a high affinity endogenous inhibitor of
cathepsins, it is primarily active in the extracellular matrix (Kopitar-Jerala, 2006). Studies
investigating changes and localization of cystatin C in DC cells indicate cystatin C is not
localized to lysosomal vesicles and furthermore do control antigen presentation (ZavasnikBergant T, 2005; Sukkari, 2003). In contrast, other studies show decreased levels of
cystatin C increase cathepsin S activity and control intracellular levels and trafficking of
MHC class II in DC (Boes, 2005; Kitamura, 2005; Pierre,1998). Images generated from
the ImageStream® Cell Analysis System demonstrated cathepsin substrate products
remained localized within intracellular acidic vesicles in LPS-stimulated cells. Therefore,
the significance of decreased cystatin C mRNA expression on intracellular cathepsin
activities in LPS-stimulated cells remains unclear. Furthermore, while cystatin C was
reduced the level was not statistically significant, supporting a minimal role for cystatin C
in the regulation of cathepsins in macrophages responding to LPS.
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LPS and PGN increased the extracellular activity of cathepsins. Decreases in the
level of cystatin C correlated with increased cathepsin activities in culture supernatants
from TLR-stimulated cells. Furthermore, the secreted activity of Cat B and S from cells
treated with 10 mM ammonium chloride/mannose-6-phosphate was lower than that
observed for LPS-stimulated cells. Several mechanisms may contribute to this
phenomenon. Cathepsins are regulated on multiple levels, and protein expression was not
investigated in these studies. LPS may increase translation of these enzymes, thereby
increasing the overall protein levels. The post-transcriptional regulation of cathepsins has
not been extensively studied and the effects LPS may exert remain unknown. One way
cathepsins regulate their intracellular levels is by enzyme secretion (Chapman, 2006;
Honey, 2003). Therefore, an overload of proteases in intracellular vesicles would lead to
the secretion of these enzymes. LPS stimulation could also cause the acidification of the
culture medium, thereby promoting enzyme activation. The extracellular
microenvironment of inflamed tissues can be acidic enough to allow cathepsins to remain
active (Gatenby, 2006). Alternatively, while LPS decreased cystatin C gene expression,
this probably did not occur in cells treated with ammonium chloride/mannose-6-phosphate,
thereby allowing cystatin C to retain its regulation of secreted cathepsins. Most likely, a
combination of these mechanisms contributes to the increased extracellular cathepsin
activities. The level of extracellular enzymatic activity is nominal compared to intracellular
levels. However, these studies were performed at 24 h and did not investigate the
extracellular accumulation of these proteases over an extended time, which would be more
representative of chronic inflammation. These results suggest LPS decreases cystatin C
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gene expression contributing to increases in extracellular activity of cathepsins, thereby
promoting their involvement in tissue destruction.
Regardless of the stimulus utilized, the fold-increase in Cat B activity is the lowest
of all three cathepsins. It has been suggested Cat B is not highly active in macrophages,
however the level of gene expression was comparable to that of Cat L and S. LPS alters
the endosomal/lysosomal location of these proteases, however this effect in the context of
other TLR ligands has not been found. (Lautwein, 2002). Recruitment of cathepsins to
more acidic endosomal compartments promotes enzyme activation, which may not occur
with other TLR ligands. TLR-4 is internalized upon ligand binding and acidification of
endosomal compartments is required for ligand-receptor disassociation, which would
activate cathepsins (Kobayashi, 2006). Furthermore, a recent study indicates endocytosis
of TLR-4 is required to initiate MyD88-independent signaling cascades (Kagan, 2008).
Although fluorescence generated by LysoTracker DND-26 was higher in LPS-activated
cells, it could not be determined if changes in acidity, or increases in the size or number of
acidic vesicles contributed to the increase in cathepsin activities. It is likely multiple
mechanisms, including changes in localization within acidic compartments, contribute to
the differential regulation of these proteases during the response to TLR ligands.
TLR agonists and antagonists are also currently proposed for various
immunotherapies. TLR agonists are currently under investigation for use as vaccine
adjuvants to promote immune response. Cathepsins are upregulated in a number of
diseases and TLR activation of cells can alter the severity of disease states. These studies
indicate patients with chronic inflammatory diseases involving the upregulation of
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cathepsins may not be suitable candidates for vaccines using TLR agonists. On the other
hand, the increase in cathepsin activities in TLR-activated cells appears to be primarily
mediated by cytokines. A number of cytokines are currently targeted for drug therapy,
including TNF-α and IL-1β. Both neutralizing antibodies, soluble receptors and receptor
antagonists are being utilized to treat chronic inflammatory diseases, such as RA.
Cathepsins are increased in the synovial joints from patients with RA. An interesting study
would be to investigate whether patients undergoing anti-cytokine therapy have decreased
levels of cysteine cathepsins compared to patients receiving alternative therapies.
Altogether, these studies indicate anti-cytokine therapies could be useful in preventing the
upregulation of cysteine cathepsins that occurs in TLR-activated cells.
Cannabinoid Inhibition of Cysteine Cathepsin Upregulation
Cannabinoids, including the major psychoactive component of marijuana, THC,
modulate a multitude of immune responses. LPS is often used as a classical model of
inflammation. LPS-stimulated P388D1 macrophages have increased cysteine cathepsin
activities. P388D1 macrophages lacked mRNA expression of the CB1 receptor however
expressed CB2 mRNA in resting and LPS-activated states. LPS-induced upregulation of
cathepsins was reduced by cannabinoids THC and CP55940. The effects of THC could not
be attributed to cell death or downregulation of the receptors required for a LPS response.
Utilizing a macrophage cell line genetically deficient for the CB2 receptor, the role of this
receptor was investigated. Cannabinoid modulation of cysteine cathepsins was absent in
CB2-/- macrophages. These results suggest a CB2 selective agonists could be used as a
possible therapeutic to control cysteine cathepsin upregulation during inflammation.
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LPS significantly increased Cat B, L and S activities in P388D1 macrophages.
THC and CP55940 reduced the level of increased cathepsin activities, however CP55940
was less effective than THC. THC has lower CB1 and CB2 receptor affinities than
CP55940 and acts as a partial receptor agonist. CP55940, HU-210, and WIN55212 have
high affinities for both cannabinoid receptors, acting as full agonist. A biphasic effect was
observed when investigating the effect of THC on the modulation of cysteine cathepsins.
Biphasic effects have been observed in a number of studies. For example, TNF-α
production is inhibited by nM concentrations of THC but stimulated by µM concentrations
(Pertwee, 2005). Biphasic effects are also observed in immune modulation of cannabinoids
on macrophage co-stimulatory activity and antigen processing (Chuchawankul, 2004;
Matveyeva, 2000). Cannabinoids also produce biphasic inhibition of cAMP as well as
behavioral and stress related responses (Little, 1991; Viveros, 2007). In terms of THC, a
possible reason for a biphasic effect is that THC at µM concentrations can behave as a
CB2 receptor antagonist rather than as an agonist (Pertwee, 2008). Differential effects
among the various cannabinoid agonists are also reported in several studies (Cabral, 2005;
Pertwee, 2005). For example, THC and anandamide inhibit pro-inflammatory cytokine
production by peripheral blood monocytes, however increases in IL-10 production are
specific to THC and do not occur with anandamide (Cabral, 2005). The inhibition of nitric
oxide production by RAW264.7 macrophages occurs with palmitoylethanolamide,
WIN55212, and CP55940, however CP55940 is less effective and requires higher
concentrations (Ross, 2000). The necessity for higher concentrations of CP55940 have also
been observed in studies investigating the effects of cannabinoids on macrophage
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chemotaxis and pro-inflammatory cytokine production by LPS-stimulated microglial cells
(Klein, 2005; 2006; Raborn, 2007). In my studies, CP55940 decreased cathepsin
upregulation in LPS-stimulated cells but complete inhibition was not observed. Although
LPS stimulation did not alter expression of CB2 receptor mRNA, receptor-coupling
efficiency may have been enhanced. This would lead to increased potency of THC, a
partial agonist, while not affecting the full agonist CP55940 potency.
Multiple reports have indicated the immune modulatory effects of cannabinoids
may be due to the induction of apoptosis or inhibition of cell proliferation (Guzman, 2005).
Cell proliferation of P388D1 cells was abolished when cells were cultured with LPS. Cell
numbers from medium control cultures treated with cannabinoids were only slightly lower
than vehicle control cells, indicating the effect on cell proliferation was minimal.
Interestingly, cannabinoid treatment of cells appeared to impair the LPS-induced inhibition
of cell proliferation. Cannabinoid receptor signaling cascades can lead to the activation of
PI3K/Akt, which promotes cell survival (Guzman, 2005). The significance of this pathway
is discussed in greater detail below, however it may contribute to the proliferation
observed in cannabinoid-treated, LPS-stimulated cells. Long-term cannabinoid exposure of
glioma cells and other cancer cell lines induces apoptosis. The induction of apoptosis in
glioma cells is partially mediated by the accumulation of ceramide (Guzman, 2005).
Cannabidiol induces apoptosis in primary lymphocytes, which is associated with oxidative
stress and activation of caspase-8 (Wu, 2007). Cannabinoid-induced apoptosis of human
lung cancer cells, H460, colorectal cancer cells and Jurkat T cells are mediated through
mitochondrial pathways involving the induction of pro-apoptotic Bcl-2 family member,
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BAD (Anthansiou, 2007; Greenhough, 2007; Jia, 2006). In the majority of these studies,
10 µM or higher THC concentrations are required for apoptosis. The possibility that cell
apoptosis contributed to the effects of cannabinoids on cysteine cathepsins was
investigated. THC did not induce apoptosis of P388D1 macrophages, even at
concentrations as high as10 µM. Furthermore, cell viability utilizing trypan blue exclusion
indicated necrotic cell death also did not occur. Overall, my results indicate cell
proliferation, apoptosis and necrosis were not involved in THC-mediated modulation of
cathepsin activities.
Studies have shown the immune modulating effects of cannabinoids can be
mediated through cannabinoid CB1 and/or CB2 receptors. CB1 receptor is predominantly
expressed in cells of the CNS, whereas immune cells primarily express the CB2 receptor
(Bouaboula,1993; Matsuda, 1990; Munro, 1993). This study investigated the role of CB1
and CB2 receptors in cannabinoid modulation of cysteine cathepsins. P388D1 cells lacked
CB1 mRNA expression in resting and LPS-activated states, however CB2 mRNA was
readily detected. The lack of CB1 receptor expression in P388D1 cells suggested the
inhibitory effects of THC were mediated through the CB2 receptor. A number of
cannabinoid immune modulating effects are mediated through the cannabinoid receptors.
Inhibition of LPS-induced nitric oxide production in RAW264.7 macrophages by
WIN55212 is attenuated by the CB2 receptor selective antagonist SR144528 (Ross, 2000).
In contrast, the effects mediated by palmitoylethanolamide are inhibited by CB1 receptor
antagonist, SR141716A (Ross, 2000). In murine models of enodtoxic shock, cannabinoids
are protective (Klein, 2005; Cabral, 2005). Furthermore, fever induced in mice by
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intraperitoneal LPS injection is attenuated by WIN55212 but is ablated by treatment with
CB1 and CB2 receptor antagonists (Benamar, 2007). These studies indicate both CB1 and
CB2 are involved in cannabinoid modulation of in vivo LPS responses. The specific roles
for cannabinoid receptors in macrophage LPS responses in vitro have not been extensively
studied. Some studies investigating receptor specific effects of cannabinoids on
macrophage functions emphasize a role for the CB2 receptor. Chemotaxis of macrophages
in response to RANTES is inhibited by THC and CP55940. SR144528 reversed the effects
of CP55940, furthermore the inhibitory effects of THC were not observed in CB2-/macrophages (Raborn, 2007). Co-stimulatory activity of peritoneal macrophages is
inhibited by THC, which is also reversed by SR14528 and absent in cells from CB2-/- mice
(Buckly, 2008; Chuchawankul, 2004). Interestingly, THC inhibits glioma cell invasion by
downregulating MMP-2, which is reversed by the CB2 receptor antagonist (Blazquez,
2008). As mentioned previously, MMP and cathepsins are both involved in tumor
angiogenesis and tissue destruction. Upon further investigation into the role of CB2 in
cannabinoid modulation of cysteine cathepsins, I discovered THC did not alter cathepsin
activities in macrophages lacking CB2 receptor expression due to a genetic deficiency. The
CB2-/- macrophages also lacked expression of CB1 mRNA in resting or LPS-activated
states. The absence of CB1 expression in P388D1 cells combined with the lack of
cannabinoid modulation in CB2-/- macrophages indicates THC modulation of cysteine
cathepsins in LPS-stimulated macrophages is CB2 receptor-mediated. Furthermore, this
implies CB2 receptor expression is required for the modulation of cathepsins by
cannabinoids during an inflammatory response.
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Cannabinoids alter a variety of responses typical of LPS-stimulated immune cells.
LPS-activated splenocytes treated with THC produce decreased levels of type I IFN
(Klein, 2005), and treatment of these cells with WIN55212 or HU-210 also decreases
TNF-α production (Klein, 2005). Endogenous cannabinoids, AEA and 2-AG as well as
THC, decrease IL-6 production by LPS-activated J774 macrophages (Cabral, 2005).
Alveolar macrophages isolated from chronic marijuana users have decreased IL-1β, TNFα and IL-6 production upon stimulation with LPS (Baldwin, 1997). THC decreases TNF-α
production by LPS-stimulated RAW264.7 macrophages by altering the conversion of
TNF-α to the secreted form (Klein, 2005; Cabral, 2005). Due to the multitude of LPS
responses altered by cannabinoids, I investigated the effects of THC on cell surface
expression of the LPS receptor and co-receptor, TLR-4 and CD14. THC did not alter the
cell surface expression of the functional LPS receptor, TLR-4/MD2, or co-receptor, CD14.
This rules out the possibility THC-induced downregulation of the LPS receptor molecules
is responsible for the immune modulating effects observed in these studies. However, THC
may interfere with the downstream signaling cascade.
Attenuation of LPS-induced iNOS production in RAW264.7 macrophages by THC is
associated with decreased NFκB activation (Jeon, 1996). NFκB is a master regulator of
pro-inflammatory cytokines and is rapidly activated by TLR-4 signaling cascade (Chapter
1, Figure 1). TNF-α production by LPS-stimulated macrophages is NFκB-dependent.
TNF-α and IL-1β contributed to the increased activity of Cat B and L in macrophages.
Therefore, cannabinoid receptor signaling may interfere with TLR-4 signaling cascades
leading to NFκB activation, ultimately inhibiting the production of pro-inflammatory
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cytokines involved in regulating cathepsins (Figure 24). Alternatively, PI3K and MAPK
activation are associated with cannabinoid receptor signaling (Chapter 1, Figure 2)
(Howlett, 2005; Sanchez, 2003). The MAP kinases, ERK1/2 and JNK1/2, are activated by
both TLR-4 and cannabinoid receptor signaling cascades. The specific role of these kinases
in the LPS responses is not clear. However, they may promote an anti-inflammatory
response that occurs to control inflammation in LPS-activated cells. This raises the
possibility MAPK activation by cannabinoids may increase anti-inflammatory mediators,
which decreases LPS-induced inflammatory responses. Recently a critical role for the
p110β subunit of PI3K was identified in LPS-induced nitric oxide production by
RAW264.7 cells (Tsukamoto, 2008). Genetic deficiency of p110β leads to a loss of Akt
activation by PI3K and increases production of nitric oxide and IL-12 by LPS-activated
macrophages. The p110β subunit of PI3K is involved in the negative regulation of LPS
activation. While Gβγ subunits commonly associate with PI3Kγ, the p110β subunit is also
activated by Gβγ subunits (Tsukamoto, 2008). Therefore, cannabinoid regulation of LPS
responses may involve the activation of negative feedback regulators, such as p110β.
This study is the first report indicating cannabinoids can modulate cysteine
cathepsins during an inflammatory response. THC has been used to treat pain, asthma,
glaucoma, AIDS, cancer and a number of other chronic inflammatory diseases (Benamar,
2006). LPS activation of macrophages leads to the production of pro-inflammatory
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Figure 24. Model of inflammatory regulation of cysteine cathepsins.
Binding of LPS induces TLR-4 receptor dimerization and the association of adaptor
molecules MyD88 and TRAM/TRIF. This in turn leads to the activation of TBK1, IKK
and MAPK signaling cascades and ultimately the activation of transcription factors NFκB,
AP-1, and IRFs, which promote the production of pro-inflammatory cytokines. Proinflammatory cytokines produced in response to LPS increase cathepsin activities and
decrease levels of cystatin C. THC binding to the CB2 receptor induces the disassociation
of G protein subunits. The Gα subunit interacts with andenyl cyclase, decreasing cAMP
levels. The βγ subunit activate PI3K and MKKs, leading to a reduction in proinflammatory cytokine production, thereby preventing increased cathepsin activities.
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cytokines that contribute to increases in cysteine cathepsin activities. Anti-cytokine
therapies are currently utilized to treat some chronic inflammatory diseases, however they
are not suitable for all patients. These results indicate THC via the CB2 receptor interfered
with increased cysteine cathepsin activities during an inflammatory response. A number of
effects cannabinoids exert on inflammatory responses are mediated through the CB2
receptor. Due to the lack of psychoactive effects, CB2 receptor-selective agonists are
currently being investigated as therapeutics to treat chronic inflammatory diseases. These
findings support the possibility of CB2 receptor-selective agonists as therapeutic agents for
chronic inflammatory diseases to prevent cathepsin involvement in pathological tissue
destruction.
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Supplemental Figure 1. LPS increases cathepsin activity in a dose dependent manor.
Macrophages were cultured in medium with or without the indicated doses of LPS for 24
h. Cells were harvested, incubated with the cathepsin selective MR conjugated substrates
and analyzed by FCM. Histograms are representative of two separate experiments.
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Supplementary Figure 2. Enhanced cathepsin activities correlate with increasing
concentrations of PGN.
Macrophages were incubated in medium without or with the indicated doses of PGN for 24
h. Cells were harvested, washed, viability was assessed and cathepsin activities were
measured using AMC conjugated substrates. Data are the mean ± SD from 3 or more
separate experiments.
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Supplementary Figure 3. Analysis of cathepsin upregulation in response to various doses
of Poly I:C.
Macrophages were incubated in medium with or without various doses of Poly I:C for 24
h. Cells were harvested and cathepsin activities were assessed using AMC conjugated
substrates. Data are mean ± SD of fold increase over medium control from two separate
experiments.
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Supplementary Figure 4. Semi-quantitative Real Time-PCR analysis of Cat B, L and
cystatin C mRNA expression in macrophages cultured without or with LPS.
Macrophages were incubated without or with 1 µg/ml LPS for 24 h. Cells were harvested
and RNA isolation was performed. Quantitative Real Time-PCR using SYBR GreenER™
Two-Step qRT-PCR kit was performed. The BIO-RAD iCycler was utilized for
amplification and analysis. Data are relative expression normalized to β-actin from 3
separate samples run in unison without triplicates of each sample.
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